452 results on '"Vincenzo, R."'
Search Results
202. Biochemical and behavioural indices of striatal dopaminergic activity after 6-methyltetrahydropterin
- Author
-
Olgiati, Vincenzo R., primary, Algeri, Sergio, additional, and Stramentinoli, Giorgio, additional
- Published
- 1987
- Full Text
- View/download PDF
203. Anti-proliferative activity of a new class of taxanes (14β-hydroxy-10-deacetylbaccatin III derivatives) on multidrug-resistance-positive human cancer cells. Int. J. Cancer, 72, 844-850 (1997).
- Author
-
Distefano, M., Scambia, G., Ferlini, C., Gaggini, C., De Vincenzo, R., Riva, A., Bombardelli, E., Ojima, I., Fattorossi, A., Benedetti Panici, P., and Mancuso, S.
- Published
- 1998
- Full Text
- View/download PDF
204. High-risk HPV-positive and -negative high-grade cervical dysplasia: Analysis of 5-year outcomes
- Author
-
Giovanni Scambia, Mario Malzoni, Lavinia Mosca, Lorenzo Aguzzoli, Nicola Colacurci, Gabriele Carlinfante, Marco Petrillo, Stefano Greggi, Paolo Vercellini, Antonio Cianci, Francesco Raspagliesi, Andrea Giannini, Andrea Ciavattini, Viola Liberale, Sara Bosio, Luca Giannella, Maurizio Serati, Rocco Guerrisi, Simone Ferrero, Michele Desiato, Pierandrea De Iaco, Anna Myriam Perrone, Giorgio Bogani, Fabio Ghezzi, Biagio Contino, Francesca Falcone, Arsenio Spinillo, Francesco Sopracordevole, Claudia Brusadelli, Antonio Simone Laganà, Simona Ruisi, Maria Grazia Matarazzo, Pierluigi Benedetti Panici, Paola Carunchio, Giuseppe Sarpietro, Alessandro Ghelardi, Barbara Gardella, Francesco Plotti, Alice Bergamini, Margherita Fischetti, Antonino Ditto, Gian Franco Zannoni, Gabriella Ferrandina, Vincenzo Dario Mandato, Valentina Chiappa, Violante Di Donato, Raffaele Tinelli, Ermelinda Monti, Roberto Angioli, Salvatore Dessole, Annunziata Carlea, Ciro Pinelli, Fulvio Zullo, Salvatore Lopez, Sara Lovati, Tommaso Simoncini, Maria Giovanna Salerno, Mauro Signorelli, Rosa De Vincenzo, Cono Scaffa, Jvan Casarin, Chiara Borghi, Cristina Donfrancesco, Ludovico Muzii, Giovanni D'ippolito, Gaetano Valenti, Andrea Dell'Acqua, Giulia Dondi, Bogani, G., Sopracordevole, F., Di Donato, V., Ciavattini, A., Ghelardi, A., Lopez, S., Simoncini, T., Plotti, F., Casarin, J., Serati, M., Pinelli, C., Valenti, G., Bergamini, A., Gardella, B., Dell'Acqua, A., Monti, E., Vercellini, P., Fischetti, M., D'Ippolito, G., Aguzzoli, L., Mandato, V. D., Carunchio, P., Carlinfante, G., Giannella, L., Scaffa, C., Falcone, F., Borghi, C., Ditto, A., Malzoni, M., Giannini, A., Salerno, M. G., Liberale, V., Contino, B., Donfrancesco, C., Desiato, M., Perrone, A. M., Dondi, G., De Iaco, P., Chiappa, V., Ferrero, S., Sarpietro, G., Matarazzo, M. G., Cianci, A., Bosio, S., Ruisi, S., Guerrisi, R., Brusadelli, C., Mosca, L., Lagana', A. S., Tinelli, R., Signorelli, M., De Vincenzo, R., Zannoni, G. F., Ferrandina, G., Lovati, S., Petrillo, M., Dessole, S., Carlea, A., Zullo, F., Angioli, R., Greggi, S., Spinillo, A., Ghezzi, F., Colacurci, N., Muzii, L., Benedetti Panici, P., Scambia, G., Raspagliesi, F., Bogani G., Sopracordevole F., Di Donato V., Ciavattini A., Ghelardi A., Lopez S., Simoncini T., Plotti F., Casarin J., Serati M., Pinelli C., Valenti G., Bergamini A., Gardella B., Dell'acqua A., Monti E., Vercellini P., Fischetti M., D'ippolito G., Aguzzoli L., Mandato V.D., Carunchio P., Carlinfante G., Giannella L., Scaffa C., Falcone F., Borghi C., Ditto A., Malzoni M., Giannini A., Salerno M.G., Liberale V., Contino B., Donfrancesco C., Desiato M., Perrone A.M., Dondi G., De Iaco P., Chiappa V., Ferrero S., Sarpietro G., Matarazzo M.G., Cianci A., Bosio S., Ruisi S., Guerrisi R., Brusadelli C., Mosca L., Lagana' A.S., Tinelli R., Signorelli M., De Vincenzo R., Zannoni G.F., Ferrandina G., Lovati S., Petrillo M., Dessole S., Carlea A., Zullo F., Angioli R., Greggi S., Spinillo A., Ghezzi F., Colacurci N., Muzii L., Benedetti Panici P., Scambia G., and Raspagliesi F.
- Subjects
0301 basic medicine ,Adult ,medicine.medical_specialty ,HPV ,Uterine Cervical Neoplasm ,Prognosi ,CIN ,conization ,negative ,positive ,Conization ,Uterine Cervical Neoplasms ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Risk Factors ,Retrospective Studie ,medicine ,Humans ,Cervical Intraepithelial Neoplasia ,Prospective cohort study ,Propensity Score ,Papillomavirus Infection ,Retrospective Studies ,Obstetrics ,Proportional hazards model ,business.industry ,Risk Factor ,Papillomavirus Infections ,Obstetrics and Gynecology ,Retrospective cohort study ,Middle Aged ,Prognosis ,medicine.disease ,Negative ,Uterine Cervical Dysplasia ,female genital diseases and pregnancy complications ,030104 developmental biology ,Settore MED/40 - GINECOLOGIA E OSTETRICIA ,Oncology ,Dysplasia ,030220 oncology & carcinogenesis ,Cohort ,Propensity score matching ,Population study ,Female ,business ,Positive ,Cohort study ,Human - Abstract
Objective: To evaluate the outcomes of high-risk (HR) HPV-positive and -negative women affected by high-grade cervical dysplasia. Methods: This is a retrospective multi-institutional study. Medical records of consecutive patients with high-grade cervical dysplasia undergoing conization between 2010 and 2014 were retrieved. All patients included had at least 5 years of follow-up. A propensity-score matching was adopted in order to reduce the presence of confounding factors between groups. Kaplan-Meir and Cox hazard models were used to estimate 5-year outcomes. Results: Overall, data of 2966 women, affected by high-grade cervical dysplasia were reviewed. The study population included 1478 (85%) and 260 (15%) women affected by HR-HPV-positive and HR-HPV-negative high-grade cervical dysplasia. The prevalence of CIN2 and CIN3 among the HR-HPV-positive and -negative cohort was similar (p = 0.315). Patients with HR-HPV-positive high-grade cervical dysplasia were at higher risk of 5-year recurrence (after primary conization) that HR-HPV-negative patients (p < 0.001, log-rank test). Via multivariate analysis, HR-HPV-negative women were at low risk of recurrence (HR: 1.69 (95%CI: 1.05, 4.80); p = 0.018, Cox Hazard model). A propensity-score matched comparison was carried out in order to reduce biases that are related to the retrospective study design. In comparison to HR-HPV-negative patients, thosewith HR-HPV-positive CIN3 was associate with a 8-fold increase in the risk of recurrence (p < 0.001, log-rank test). Conclusions: HR-HPV-negative high-grade cervical dysplasia is not uncommon, accounting for 15% of our study population. Those patients experience more favorable outcomes than patients with documented HR-HPV infection(s). Further prospective studies are needed to corroborate our data.
- Published
- 2021
205. Assessing the Long-Term Role of Vaccination against HPV after Loop Electrosurgical Excision Procedure (LEEP): A Propensity-Score Matched Comparison
- Author
-
Mario Malzoni, Gaetano Valenti, Lavinia Mosca, Stefano Ferla, Nicola Colacurci, Paolo Vercellini, Antonio Cianci, Rocco Guerrisi, Claudia Brusadelli, Biagio Contino, Giovanni Scambia, Andrea Ciavattini, Umberto Leone Roberti Maggiore, Pierluigi Benedetti Panici, Gabriella Ferrandina, Stefano Greggi, Gabriele Carlifante, Giorgio Bogani, Barbara Gardella, Margherita Fischetti, Simone Ferrero, Maurizio Serati, Ciro Pinelli, Salvatore Lopez, Fulvio Zullo, Anna Myriam Perrone, Mauro Signorelli, Rosa De Vincenzo, Andrea Giannini, Raffaele Tinelli, Vincenzo Dario Mandato, Jvan Casarin, Arsenio Spinillo, Francesco Sopracordevole, Francesco Plotti, Violante Di Donato, Viola Liberale, Maria Grazia Matarazzo, Antonino Ditto, Annunziata Carlea, Ermelinda Monti, Lorenzo Aguzzoli, Maria Giovanna Salerno, Cono Scaffa, Francesca Falcone, Michele Desiato, Valentina Chiappa, Pierandrea De Iaco, Roberto Angioli, Alice Bergamini, Salvatore Dessole, Marco Petrillo, Simona Ruisi, Francesco Raspagliesi, Giulia Dondi, Fabio Ghezzi, Giovanni D'ippolito, Sara Bocio, Andrea Dell'Acqua, Giuseppe Sarpietro, Chiara Borghi, Alessandro Ghelardi, Paola Carunchio, Luca Gianella, Tommaso Simoncini, Cristina Donfrancesco, Ludovico Muzii, Gian Franco Zannoni, Bogani, G., Raspagliesi, F., Sopracordevole, F., Ciavattini, A., Ghelardi, A., Simoncini, T., Petrillo, M., Plotti, F., Lopez, S., Casarin, J., Serati, M., Pinelli, C., Valenti, G., Bergamini, A., Gardella, B., Dell'Acqua, A., Monti, E., Vercellini, P., D'Ippolito, G., Aguzzoli, L., Mandato, V. D., Carunchio, P., Carlifante, G., Giannella, L., Scaffa, C., Falcone, F., Ferla, S., Borghi, C., Ditto, A., Malzoni, M., Giannini, A., Salerno, M. G., Liberale, V., Contino, B., Donfrancesco, C., Desiato, M., Perrone, A. M., Dondi, G., De Iaco, P., Maggiore, U. L. R., Signorelli, M., Chiappa, V., Ferrero, S., Sarpietro, G., Matarazzo, M. G., Cianci, A., Bocio, S., Ruisi, S., Guerrisi, R., Brusadelli, C., Mosca, L., Tinelli, R., De Vincenzo, R., Zannoni, G. F., Ferrandina, G., Dessole, S., Angioli, R., Greggi, S., Spinillo, A., Ghezzi, F., Colacurci, N., Fischetti, M., Carlea, A., Zullo, F., Muzii, L., Scambia, G., Panici, P. B., Di Donato, V., Bogani G., Raspagliesi F., Sopracordevole F., Ciavattini A., Ghelardi A., Simoncini T., Petrillo M., Plotti F., Lopez S., Casarin J., Serati M., Pinelli C., Valenti G., Bergamini A., Gardella B., Dell'acqua A., Monti E., Vercellini P., D'ippolito G., Aguzzoli L., Mandato V.D., Carunchio P., Carlifante G., Giannella L., Scaffa C., Falcone F., Ferla S., Borghi C., Ditto A., Malzoni M., Giannini A., Salerno M.G., Liberale V., Contino B., Donfrancesco C., Desiato M., Perrone A.M., Dondi G., De Iaco P., Maggiore U.L.R., Signorelli M., Chiappa V., Ferrero S., Sarpietro G., Matarazzo M.G., Cianci A., Bocio S., Ruisi S., Guerrisi R., Brusadelli C., Mosca L., Tinelli R., De Vincenzo R., Zannoni G.F., Ferrandina G., Dessole S., Angioli R., Greggi S., Spinillo A., Ghezzi F., Colacurci N., Fischetti M., Carlea A., Zullo F., Muzii L., Scambia G., Panici P.B., and Di Donato V.
- Subjects
medicine.medical_specialty ,HPV ,Cost effectiveness ,Immunology ,lcsh:Medicine ,Lower risk ,Article ,03 medical and health sciences ,conization ,0302 clinical medicine ,Primary prevention ,Drug Discovery ,medicine ,Recurrent disease ,LEEP ,Pharmacology (medical) ,030212 general & internal medicine ,leep ,vaccination ,Pharmacology ,Obstetrics ,business.industry ,lcsh:R ,medicine.disease ,Vaccination ,Settore MED/40 - GINECOLOGIA E OSTETRICIA ,Infectious Diseases ,Loop electrosurgical excision procedure ,Dysplasia ,030220 oncology & carcinogenesis ,Propensity score matching ,business - Abstract
Background: Primary prevention through vaccination is a prophylactic approach aiming to reduce the risk of developing human papillomavirus (HPV)-related lesions. No mature and long-term data supported the adoption of vaccination in women undergoing conization. Methods: This is a retrospective multi-institutional study. Charts of consecutive patients undergoing conization between 2010 and 2014 were collected. All patients included had at least 5 years of follow-up. We compared outcomes of patients undergoing conization plus vaccination and conization alone. A propensity-score matching algorithm was applied in order to reduce allocation biases. The risk of developing recurrence was estimated using Kaplan-Meir and Cox hazard models. Results: Overall, charts of 1914 women were analyzed. The study group included 116 (6.1%) and 1798 (93.9%) women undergoing conization plus vaccination and conization alone, respectively. Five-year recurrence rate was 1.7% (n = 2) and 5.7% (n = 102) after conization plus vaccination and conization alone, respectively (p = 0.068). After the application of a propensity-score matching, we selected 100 patients undergoing conization plus vaccination and 200 patients undergoing conization alone. The crude number of recurrences was 2 (2%) and 11 (5.5%) for patients undergoing conization plus vaccination and conization alone, respectively (p = 0.231). Vaccination had no impact on persistent lesions (no negative examination between conization and new cervical dysplasia, p = 0.603), but reduced the risk of recurrent disease (patients who had at least one negative examination between conization and the diagnosis of recurrent cervical dysplasia, p = 0.031). Conclusions: Patients having vaccination experience a slightly lower risk of recurrence than women who had not, although not statistically significantly different. Further evidence is needed to assess the cost effectiveness of adopting vaccination in this setting.
- Published
- 2020
- Full Text
- View/download PDF
206. Inhibitory effect of quercetin on primary ovarian and endometrial cancers and synergistic activity with cis-diamminedichloroplatinum(II)
- Author
-
Scambia, G, Ranelletti, F.O., Panici, P.B., Piantelli, M, Bonanno, G, De Vincenzo, R, Ferrandina, G, Maggiano, N, Capelli, A, and Mancuso, S
- Published
- 1993
- Full Text
- View/download PDF
207. Anti-proliferative activity of a new class of taxanes (14β-hydroxy-10-deacetylbaccatin III derivatives) on multidrug-resistance-positive human cancer cells. <TOGGLE>Int. J. Cancer,</TOGGLE> 72, 844850 (1997)
- Author
-
Distefano, M., Scambia, G., Ferlini, C., Gaggini, C., Vincenzo, R. De, Riva, A., Bombardelli, E., Ojima, I., Fattorossi, A., Panici, P. Benedetti, and Mancuso, S.
- Abstract
Distefano, M., Scambia, G., Ferlini, C., Gaggini, C., De Vincenzo, R., Riva, A., Bombardelli, E., Ojima, I., Fattorossi, A., Benedetti Panici, P. and Mancuso, S., Anti-proliferative activity of a new class of taxanes (14β-hydroxy-10-deacetylbaccatin III derivatives) on multidrug-resistance-positive human cancer cells. Int. J. Cancer, 72, 844N850 (1997). The incorrect version of Figure 2 was published in the above-noted article. The correct version of the figure is printed here along with the legend. The Authors regret the error.
- Published
- 1998
- Full Text
- View/download PDF
208. Recurrence rate after loop electrosurgical excision procedure (LEEP) and laser Conization: A 5-year follow-up study
- Author
-
Giuseppe Sarpietro, Giovanni D'ippolito, Gabriele Carlinfante, Marco Petrillo, Claudia Brusadelli, Paola Carunchio, Maria Giovanna Salerno, Cono Scaffa, Arsenio Spinillo, Francesco Sopracordevole, Gian Franco Zannoni, Violante Di Donato, Francesco Plotti, Viola Liberale, Francesco Raspagliesi, Giovanni Scambia, Fabio Ghezzi, Antonino Ditto, Simona Ruisi, Michele Desiato, Ermelinda Monti, Valentina Chiappa, Pierandrea De Iaco, Stefano Greggi, Francesca Falcone, Lorenzo Aguzzoli, Roberto Angioli, Salvatore Dessole, Paolo Vercellini, Antonio Cianci, Gaetano Valenti, Giulia Dondi, Luca Giannella, Maurizio Serati, Andrea Giannini, Sara Bosio, Margherita Fischetti, Raffaele Tinelli, Tommaso Simoncini, Cristina Donfrancesco, Ludovico Muzii, Nicola Colacurci, Alessandro Ghelardi, Andrea Dell'Acqua, Ciro Pinelli, Salvatore Lopez, Rocco Guerrisi, Giorgio Bogani, Mauro Signorelli, Rosa De Vincenzo, Jvan Casarin, Pierluigi Benedetti Panici, Andrea Ciavattini, Lavinia Mosca, Umberto Leone Roberti Maggiore, Biagio Contino, Barbara Gardella, Vincenzo Dario Mandato, Mario Malzoni, Maria Grazia Matarazzo, Simone Ferrero, Gabriella Ferrandina, Anna Myriam Perrone, Chiara Borghi, Alice Bergamini, Bogani, G., DI DONATO, V., Sopracordevole, F., Ciavattini, A., Ghelardi, A., Lopez, S., Simoncini, T., Plotti, F., Casarin, J., Serati, M., Pinelli, C., Valenti, G., Bergamini, A., Gardella, B., Dell'Acqua, A., Monti, E., Vercellini, P., Fischetti, M., D'Ippolito, G., Aguzzoli, L., Mandato, V. D., Carunchio, P., Carlinfante, G., Giannella, L., Scaffa, C., Falcone, F., Borghi, C., Ditto, A., Malzoni, M., Giannini, A., Salerno, M. G., Liberale, V., Contino, B., Donfrancesco, C., Desiato, M., Perrone, A. M., Dondi, G., De IACO, P., LEONE ROBERTI MAGGIORE, U., Signorelli, M., Chiappa, V., Ferrero, S., Sarpietro, G., Matarazzo, M. G., Cianci, A., Bosio, S., Ruisi, S., Guerrisi, R., Brusadelli, C., Mosca, L., Tinelli, R., DE VINCENZO, R., Zannoni, G. F., Ferrandina, G., Petrillo, M., Dessole, S., Angioli, R., Greggi, S., Spinillo, A., Ghezzi, F., Colacurci, N., Muzii, L., BENEDETTI PANICI, P., Scambia, G., Raspagliesi, F., BOGANI G., DI DONATO V., SOPRACORDEVOLE F., CIAVATTINI A., GHELARDI A., LOPEZ S., SIMONCINI T., PLOTTI F., CASARIN J., SERATI M., PINELLI C., VALENTI G., BERGAMINI A., GARDELLA B., DELL'ACQUA A., MONTI E., VERCELLINI P., FISCHETTI M., D'IPPOLITO G., AGUZZOLI L., MANDATO V.D., CARUNCHIO P., CARLINFANTE G., GIANNELLA L., SCAFFA C., FALCONE F., BORGHI C., DITTO A., MALZONI M., GIANNINI A., SALERNO M.G., LIBERALE V., CONTINO B., DONFRANCESCO C., DESIATO M., PERRONE A.M., DONDI G., De IACO P., LEONE ROBERTI MAGGIORE U., SIGNORELLI M., CHIAPPA V., FERRERO S., SARPIETRO G., MATARAZZO M.G., CIANCI A., BOSIO S., RUISI S., GUERRISI R., BRUSADELLI C., MOSCA L., TINELLI R., DE VINCENZO R., ZANNONI G.F., FERRANDINA G., PETRILLO M., DESSOLE S., ANGIOLI R., GREGGI S., SPINILLO A., GHEZZI F., COLACURCI N., MUZII L., BENEDETTI PANICI P., SCAMBIA G., and RASPAGLIESI F.
- Subjects
0301 basic medicine ,Uterine Cervical Neoplasm ,Neoplasm, Residual ,Conization ,Uterine Cervical Neoplasms ,Cervix Uteri ,Laser conization ,Hpv persistence ,Cervical dysplasia ,0302 clinical medicine ,Risk Factors ,Retrospective Studie ,Aged, 80 and over ,Medical record ,Obstetrics and Gynecology ,Margins of Excision ,Middle Aged ,Oncology ,030220 oncology & carcinogenesis ,HPV ,LEEP ,Female ,Human ,Adult ,medicine.medical_specialty ,5 year follow up ,Adolescent ,Electrosurgery ,Laser ,Follow-Up Studie ,03 medical and health sciences ,Young Adult ,medicine ,Humans ,In patient ,Cervical Intraepithelial Neoplasia ,Papillomavirus Infection ,Retrospective Studies ,Aged ,business.industry ,Lasers ,Risk Factor ,Papillomavirus Infections ,Uterine Cervical Dysplasia ,medicine.disease ,Surgery ,Settore MED/40 - GINECOLOGIA E OSTETRICIA ,030104 developmental biology ,Uterine cervix ,Increased risk ,Dysplasia ,Loop electrosurgical excision procedure ,Neoplasm Grading ,Neoplasm Recurrence, Local ,business ,Follow-Up Studies - Abstract
Objective: Conization aims to remove pre-neoplastic lesions of the uterine cervix. Several techniques for conization have been compared, but evidence regarding the most effective therapeutic option is scant. Here, we aimed to compare the recurrence rate following laser conization and loop electrosurgical excision procedure (LEEP) in patients with high-grade cervical dysplasia (HSIL/CIN2+). Methods: This is a retrospective multi-institutional study. Medical records of consecutive patients with HSIL/CIN2+ undergoing conization between 2010 and 2014 were retrieved. A propensity-score matching (PSM) was applied in order to reduce allocation bias. The risk of developing recurrence was estimated using Kaplan-Meir and Cox hazard models. Results: Overall, 2966 patients had conization over the study period, including 567 (20%) and 2399 (80%) patients having laser conization and LEEP, respectively. Looking at predictors of recurrence, diagnosis of CIN3 (HR:3.80 (95%CI:2.01,7.21); p < 0.001) and HPV persistence (HR:1.81 (95%CI:1.11,2.96); p < 0.001) correlated with an increased risk of recurrence. After applying a PSM we selected 500 patients undergoing laser conization and 1000 undergoing LEEP. Patients undergoing LEEP were at higher risk of having positive surgical margins in comparison to patients undergoing laser conization (11.2% vs. 4.2%). The risk of having persistence of HPV was similar between the two groups (15.0% vs. 11.6%;p = 0.256). Five-year recurrence rate was 8.1% and 4% after LEEP and laser conization, respectively (p = 0.023). HPV persistence was the only factor associated with [5-]year recurrence after both laser conization (p = 0.003) and LEEP (p = 0.001). Conclusions: HPV persistence is the only factor associated with an increased risk of recurrence after either laser conization or LEEP. Owing to the lack of data regarding obstetrical outcomes, we are not able to assess the best therapeutic option for women with cervical dysplasia.
- Published
- 2020
209. Platelet count does not predict bleeding in cirrhotic patients: Results from the PRO-LIVER Study
- Author
-
Basili, S. a, Raparelli, V. b., Napoleone, L. b., Talerico, G. a., Corazza, G. R. c., Perticone, F. d., Sacerdoti, D. e., Andriulli, A. f., Licata, A. g., Pietrangelo, A., Picardi, A. i., Raimondo, G. j., Violi, F., Palasciano, G., D’Alitto, F., Palmieri, V. O., Santovito, D., Michele, Di, Croce, D., Brocco, G., Fasolato, S., Cecchetto, S., Bombonato, L., Bertoni, G., Restuccia, M., Andreozzi, T., Liguori, P., Caroleo, M. L., Perticone, B., Staltari, M., Manfredini, O., Giorgi, De, Averna, A., Giammanco, M., Granito, A., Pettinari, A., Marinelli, I., Bolondi, S., Falsetti, L., Salvi, L., Durante-Mangoni, A., Cesaro, E., Farinaro, F., Ragone, V., Morana, E., Ippolito, I., Iacobellis, A., Niro, A., Merla, G., Maimone, A., Cacciola, S., Varvara, I., Drenaggi, D., Staffolani, D., Vespasiani-Gentilucci, S., Galati, U., Gallo, G., Davì, P., Schiavone, G., Santilli, C., Tana, F., Soresi, C., Bianchi, Giovanni, Carderi, B., Pinto, I., Tuttolomondo, A., Ferrari, A., Gresele, G., Fierro, P., Morelli, T., Laffi, O., Romanelli, G., Arena, R. G., Stasi, U., Gasbarrini, A., Garcovich, M., Zocco, M. A., Riccardi, L., Ainora, M. E., Capeci, W., Martino, Giuseppe, Nobili, P., Cavallo, L., Frugiuele, M., Greco, P., Ventura, P., Cuoghi, C., Marcacci, M., Serviddio, G., Vendemiale, G., Villani, R., Gargano, R., Vidili, G., Cesare, Di, Masala, V., Delitala, M., Invernizzi, G., Vincenzo, P., Minno, Di, Tufano, G., Purrello, A., Privitera, F., Forgione, G., Curigliano, A., Senzolo, V., Rodríguez-Castro, M., Giannelli, K. I., Serra, G., Neri, C., Pignataro, S., Rizzetto, P., Debernardi, M., Svegliati, V. W., Bergamaschi, B. G., Masotti, G., Costanzo, M., Antonio, F., Angelico, F., Del, Ben, Polimeni, M., Proietti, L., Cangemi, M., Romiti, R., Toriello, G. F., Sperduti, F., Santangelo, N., Visioli, G., Todisco, G., Vestri, Anna, Farcomeni, R., Corrao, A., Gobbi, S., Corradini, E., Costantino, G., Tripepi, G., Angelico, M., Bolondi, L., D’Amico, G., Franchis, De, Gatta, R., Tassone, A., Anzaldi, E. J., Barone, M., Bazzini, M., Bianchi, C., Boari, P. I., Bracco, B., Buonauro, C., Buttà, A., Buzzetti, E., Calabria, S., Caradio, F., Carleo, P., Carrabba, Maria, Castorani, D., Cecchetto, L., Cicco, L., Cimini, S., Colombo, C., B. M., Vuono, De, Denegri, S., Del, Corso, Giosia, Di, Donnarumma, P., Giorgini, E., Grassi, P., Grembiale, D., Hijazi, A., Iamele, D., Lorusso, L., Marchese, G., Marra, Alberto, Masala, M., Miceli, M., Montebianco, G., Murgia, A. L., Naccarato, G., Padula, P., Pattoneri, D., Perego, P., Pesce, F., Petramala, P., Piano, L., Pinto, S., Pinna, D., Pignataro, M., Pretti, F. S., Pucci, V., Salinaro, G., Salzano, F., Santarossa, A., Scarpini, C., Scicali, F., Sirico, R., Suppressa, D., Talia, P., Torres, M., Traversa, D., Vazzana, M., Vecchio, Claudia, Vettore, R., Vitale, E., Basili, S., Raparelli, V., Napoleone, L., Talerico, G., Corazza, G.R., Perticone, F., Sacerdoti, D., Andriulli, A., Licata, A., Pietrangelo, A., Picardi, A., Raimondo, G., Violi, F., Palasciano, Giuseppe, D’Alitto, Felicia, Palmieri, Vincenzo Ostilio, Santovito, Daniela, Di Michele, Dario, Croce, Giuseppe, Brocco, Silvia, Fasolato, Silvano, Cecchetto, Lara, Bombonato, Giancarlo, Bertoni, Michele, Restuccia, Tea, Andreozzi, Paola, Liguori, Maria Livia, Caroleo, Benedetto, Perticone, Maria, Staltari, Orietta, Manfredini, Roberto, De Giorgi, Alfredo, Averna, Maurizio, Giammanco, Antonina, Granito, Alessandro, Pettinari, Irene, Marinelli, Sara, Bolondi, Luigi, Falsetti, Lorenzo, Salvi, Aldo, Durante-Mangoni, Emanuele, Cesaro, Flavio, Farinaro, Vincenza, Ragone, Enrico, Morana, Ignazio, Ippolito, Antonio, Iacobellis, Angelo, Niro, Grazia, Merla, Antonio, Maimone, Sergio, Cacciola, Irene, Varvara, Doriana, Drenaggi, Davide, Staffolani, Silvia, Vespasiani-Gentilucci, Umberto, Galati, Giovanni, Gallo, Paolo, Davì, Giovanni, Schiavone, Cosima, Santilli, Francesca, Tana, Claudio, Soresi, Maurizio, Bianchi Giovanni, Battista, Carderi, Isabella, Pinto, Antonio, Tuttolomondo, Antonino, Ferrari, Giovanni, Gresele, Paolo, Fierro, Tiziana, Morelli, Olivia, Laffi, Giacomo, Romanelli, Roberto Giulio, Arena, Umberto, Stasi, Cristina, Gasbarrini, Antonio, Garcovich, Matteo, Zocco, Maria Assunta, Riccardi, Laura, Ainora, Maria Elena, Capeci, William, Martino Giuseppe, Pio, Nobili, Lorenzo, Cavallo, Maurizio, Frugiuele, Pierluigi, Greco, Antonio, Ventura, Paolo, Cuoghi, Chiara, Marcacci, Matteo, Serviddio, Gaetano, Vendemiale, Gianluigi, Villani, Rosanna, Gargano, Ruggiero, Vidili, Gianpaolo, Di Cesare, Valentina, Masala, Maristella, Delitala, Giuseppe, Invernizzi, Pietro, Vincenzo, Ronca, Di Minno, Giovanni, Tufano, Antonella, Purrello, Francesco, Privitera, Graziella, Forgione, Alessandra, Curigliano, Valentina, Senzolo, Marco, Rodríguez-Castro, Kryssia Isabel, Giannelli, Gianluigi, Serra, Carla, Neri, Sergio, Pignataro, Pietro, Rizzetto, Mario, Debernardi, Venon Wilma, Svegliati, Baroni Gianluca, Bergamaschi, Gaetano, Masotti, Michela, Costanzo, Filippo, Antonio, Figliomeni, Angelico, Francesco, Del Ben, Maria, Polimeni, Licia, Proietti, Marco, Cangemi, Roberto, Romiti Giulio, Francesco, Toriello, Filippo, Sperduti, Nicolò, Santangelo, Giuseppe, Visioli, Giacomo, Todisco, Tommaso, Vestri Anna, Rita, Farcomeni, Alessio, Corrao, Salvatore, Gobbi, Paolo, Corradini, Elena, Costantino, Giorgio, Tripepi, Giovanni, Angelico, Mario, D’Amico, Gennaro, De Franchis, Roberto, Gatta, Angelo, Tassone, Eliezer Joseph, Anzaldi, Massimiliano, Barone, Milena, Bazzini, Cristina, Bianchi, Paola Ilaria, Boari, Benedetta, Bracco, Christian, Buonauro, Agostino, Buttà, Carmelo, Buzzetti, Elena, Calabria, Stefano, Caradio, Federica, Carleo, Pietro, Carrabba Maria, Domenica, Castorani, Luigi, Cicco, Sebastiano, Cimini, Claudia, Colombo, Barbara Maria, De Vuono, Stefano, Denegri, Andrea, Del Corso, Lisette, Di Giosia, Paolo, Donnarumma, Emilia, Giorgini, Paolo, Grassi, Davide, Grembiale, Alessandro, Hijazi, Daniel, Iamele, Luigi, Lorusso, Giusi, Marchese, Alessandra, Marra Alberto, Maria, Miceli, Giuseppe, Montebianco, Abenavoli Ludovico, Murgia, Giuseppe, Naccarato, Paola, Padula, Donatella, Pattoneri, Paolo, Perego, Francesca, Pesce, Paola, Petramala, Luigi, Piano, Salvatore, Pinto, Daniela, Pinna, Miriam, Pignataro, Francesca Serena, Pretti, Vincenzo, Pucci, Giacomo, Salinaro, Francesco, Salzano, Andrea, Santarossa, Claudia, Scarpini, Francesca, Scicali, Roberto, Sirico, Domenico, Suppressa, Patrizia, Talia, Michela, Torres, Daniele, Traversa, Matteo, Vazzana, Natale, Vecchio Claudia, Rita, Vettore, Elia, Vitale, Francesco, Basili, S, Raparelli, V, Napoleone, L, Talerico, G, Corazza, G, Perticone, F, Sacerdoti, D, Andriulli, A, Licata, A, Pietrangelo, A, Picardi, A, Raimondo, G, Violi, F, Palasciano, G, D'Alitto, F, Palmieri, V, Santovito, D, Di Michele, D, Croce, G, Brocco, S, Fasolato, S, Cecchetto, L, Bombonato, G, Bertoni, M, Restuccia, T, Andreozzi, P, Liguori, M, Caroleo, B, Perticone, M, Staltari, O, Manfredini, R, De Giorgi, A, Averna, M, Giammanco, A, Granito, A, Pettinari, I, Marinelli, S, Bolondi, L, Falsetti, L, Salvi, A, Durante-Mangoni, E, Cesaro, F, Farinaro, V, Ragone, E, Morana, I, Ippolito, A, Iacobellis, A, Niro, G, Merla, A, Maimone, S, Cacciola, I, Varvara, D, Drenaggi, D, Staffolani, S, Vespasiani-Gentilucci, U, Galati, G, Gallo, P, Davi, G, Schiavone, C, Santilli, F, Tana, C, Soresi, M, Bianchi Giovanni, B, Carderi, I, Pinto, A, Tuttolomondo, A, Ferrari, G, Gresele, P, Fierro, T, Morelli, O, Laffi, G, Romanelli, R, Arena, U, Stasi, C, Gasbarrini, A, Garcovich, M, Zocco, M, Riccardi, L, Ainora, M, Capeci, W, Martino Giuseppe, P, Nobili, L, Cavallo, M, Frugiuele, P, Greco, A, Ventura, P, Cuoghi, C, Marcacci, M, Serviddio, G, Vendemiale, G, Villani, R, Gargano, R, Vidili, G, Di Cesare, V, Masala, M, Delitala, G, Invernizzi, P, Vincenzo, R, Di Minno, G, Tufano, A, Purrello, F, Privitera, G, Forgione, A, Curigliano, V, Senzolo, M, Rodriguez-Castro, K, Giannelli, G, Serra, C, Neri, S, Pignataro, P, Rizzetto, M, Debernardi, V, Svegliati, B, Bergamaschi, G, Masotti, M, Costanzo, F, Antonio, F, Angelico, F, Del Ben, M, Polimeni, L, Proietti, M, Cangemi, R, Romiti, G, Toriello, F, Sperduti, N, Santangelo, G, Visioli, G, Todisco, T, Vestri Anna, R, Farcomeni, A, Corrao, S, Gobbi, P, Corradini, E, Costantino, G, Tripepi, G, Angelico, M, D'Amico, G, De Franchis, R, Gatta, A, Tassone, E, Anzaldi, M, Barone, M, Bazzini, C, Bianchi, P, Boari, B, Bracco, C, Buonauro, A, Butta, C, Buzzetti, E, Calabria, S, Caradio, F, Carleo, P, Carrabba Maria, D, Castorani, L, Cicco, S, Cimini, C, Colombo, B, De Vuono, S, Denegri, A, Del Corso, L, Di Giosia, P, Donnarumma, E, Giorgini, P, Grassi, D, Grembiale, A, Hijazi, D, Iamele, L, Lorusso, G, Marchese, A, Marra, A, Miceli, G, Montebianco, A, Murgia, G, Naccarato, P, Padula, D, Pattoneri, P, Perego, F, Pesce, P, Petramala, L, Piano, S, Pinto, D, Pinna, M, Pignataro, F, Pretti, V, Pucci, G, Salinaro, F, Salzano, A, Santarossa, C, Scarpini, F, Scicali, R, Sirico, D, Suppressa, P, Talia, M, Torres, D, Traversa, M, Vazzana, N, Vecchio Claudia, R, Vettore, E, Vitale, F, S Basili, V Raparelli, L Napoleone, G Talerico, G Corazza, F Perticone, D Sacerdoti, A Andriulli, A Licata, A Pietrangelo, A Picardi, G Raimondo, F Violi, MD on behalf of PRO-LIVER Collaborator, Palasciano Giuseppe, D’Alitto Felicia, Palmieri Vincenzo Ostilio, Santovito Daniela, Di Michele Dario, Croce Giuseppe, Brocco Silvia, Fasolato Silvano, Cecchetto Lara, Bombonato Giancarlo, Bertoni Michele, Restuccia Tea, Andreozzi Paola, Liguori Maria Livia, Caroleo Benedetto, Perticone Maria, Staltari Orietta, Manfredini Roberto, De Giorgi Alfredo, Averna Maurizio, Giammanco Antonina, Granito Alessandro, Pettinari Irene, Marinelli Sara, Bolondi Luigi, Falsetti Lorenzo, Salvi Aldo, Durante-Mangoni Emanuele, Cesaro Flavio, Farinaro Vincenza, Ragone Enrico, Morana Ignazio, Ippolito Antonio, Iacobellis Angelo, Niro Grazia, Merla Antonio, Maimone Sergio, Cacciola Irene, Varvara Doriana, Drenaggi Davide, Staffolani Silvia, Vespasiani-Gentilucci Umberto, Galati Giovanni, Gallo Paolo, Davi Giovanni, Schiavone Cosima, Santilli Francesca, Tana Claudio, Soresi Maurizio, Bianchi Giovanni Battista, Carderi Isabella, Pinto Antonio, Tuttolomondo Antonino, Ferrari Giovanni, Gresele Paolo, Fierro Tiziana, Morelli Olivia, Laffi Giacomo, Romanelli Roberto Giulio, Arena Umberto, Stasi Cristina, Gasbarrini Antonio, Garcovich Matteo, Zocco Maria Assunta, Riccardi Laura, Ainora Maria Elena, Capeci William, Martino Giuseppe Pio, Nobili Lorenzo, Cavallo Maurizio, Frugiuele Pierluigi, Greco Antonio, Ventura Paolo, Cuoghi Chiara, Marcacci Matteo, Serviddio Gaetano, Vendemiale Gianluigi, Villani Rosanna, Gargano Ruggiero, Vidili Gianpaolo, Di Cesare Valentina, Masala Maristella, Delitala Giuseppe, Invernizzi Pietro, Vincenzo Ronca, Di Minno Giovanni, Tufano Antonella, Purrello Francesco, Privitera Graziella, Forgione Alessandra, Curigliano Valentina, Senzolo Marco, Rodríguez-Castro Kryssia Isabel, Giannelli Gianluigi, Serra Carla, Neri Sergio, Pignataro Pietro, Rizzetto Mario, Debernardi Venon Wilma, Svegliati Baroni Gianluca, Bergamaschi Gaetano, Masotti Michela, Costanzo Filippo, Antonio Figliomeni, Angelico Francesco, Del Ben Maria, Polimeni Licia, Proietti Marco, Cangemi Roberto, Romiti Giulio Francesco, Toriello Filippo, Sperduti Nicolò, Santangelo Giuseppe, Visioli Giacomo, Todisco Tommaso, Vestri Anna Rita, Farcomeni Alessio, Corrao Salvatore, Gobbi Paolo, Corradini Elena, Costantino Giorgio, Tripepi Giovanni, Angelico Mario, D’Amico Gennaro, de Franchis Roberto, Gatta Angelo, Tassone Eliezer Joseph, Anzaldi Massimiliano, Barone Milena, Bazzini Cristina, Bianchi Paola Ilaria, Boari Benedetta, Bracco Christian, Buonauro Agostino, Buttà Carmelo, Buzzetti Elena, Calabria Stefano, Caradio Federica, Carleo Pietro, Carrabba Maria Domenica, Castorani Luigi, Cicco Sebastiano, Cimini Claudia, Colombo Barbara Maria, De Vuono Stefano, Denegri Andrea, Del Corso Lisette, Di Giosia Paolo, Donnarumma Emilia, Giorgini Paolo, Grassi Davide, Grembiale Alessandro, Hijazi Daniel, Iamele Luigi, Lorusso Giusi, Marchese Alessandra, Marra Alberto Maria, Miceli Giuseppe, Montebianco Abenavoli Ludovico, Murgia Giuseppe, Naccarato Paola, Padula Donatella, Pattoneri Paolo, Perego Francesca, Pesce Paola, Petramala Luigi, Piano Salvatore, Pinto Daniela, Pinna Miriam, Pignataro Francesca Serena, Pretti Vincenzo, Pucci Giacomo, Salinaro Francesco, Salzano Andrea, Santarossa Claudia, Scarpini Francesca, Scicali Roberto, Sirico Domenico, Suppressa Patrizia, Talia Michela, Torres Daniele, Traversa Matteo, Vazzana Natale, Vecchio Claudia Rita, Vettore Elia, Vitale Francesco, Corazza, G. R., Guidacci, Raimondo, Palasciano, G., D'Alitto, F., Palmieri, V. O., Santovito, D., Di Michele, D., Croce, G., Brocco, S., Fasolato, S., Cecchetto, L., Bombonato, G., Bertoni, M., Restuccia, T., Andreozzi, P., Liguori, M. L., Caroleo, B., Perticone, M., Staltari, O., Manfredini, R., De Giorgi, A., Averna, M., Giammanco, A., Granito, A., Pettinari, I., Marinelli, S., Bolondi, L., Falsetti, L., Salvi, A., Durante-Mangoni, E., Cesaro, F., Farinaro, V., Ragone, E., Morana, I., Ippolito, A., Iacobellis, A., Niro, G., Merla, A., Maimone, S., Cacciola, I., Varvara, D., Drenaggi, D., Staffolani, S., Vespasiani-Gentilucci, U., Galati, G., Gallo, P., Davi, G., Schiavone, C., Santilli, F., Tana, C., Soresi, M., Bianchi Giovanni, B., Carderi, I., Pinto, A., Tuttolomondo, A., Ferrari, G., Gresele, P., Fierro, T., Morelli, O., Laffi, G., Romanelli, R. G., Arena, U., Stasi, C., Gasbarrini, A., Garcovich, M., Zocco, M. A., Riccardi, L., Ainora, M. E., Capeci, W., Martino Giuseppe, P., Nobili, L., Cavallo, M., Frugiuele, P., Greco, A., Ventura, P., Cuoghi, C., Marcacci, M., Serviddio, G., Vendemiale, G., Villani, R., Gargano, R., Vidili, G., Di Cesare, V., Masala, M., Delitala, G., Invernizzi, P., Vincenzo, R., Di Minno, G., Tufano, A., Purrello, F., Privitera, G., Forgione, A., Curigliano, V., Senzolo, M., Rodriguez-Castro, K. I., Giannelli, G., Serra, C., Neri, S., Pignataro, P., Rizzetto, M., Debernardi, V. W., Svegliati, B. G., Bergamaschi, G., Masotti, M., Costanzo, F., Antonio, F., Angelico, F., Del Ben, M., Polimeni, L., Proietti, M., Cangemi, R., Romiti, G. F., Toriello, F., Sperduti, N., Santangelo, G., Visioli, G., Todisco, T., Vestri Anna, R., Farcomeni, A., Corrao, S., Gobbi, P., Corradini, E., Costantino, G., Tripepi, G., Angelico, M., D'Amico, G., De Franchis, R., Gatta, A., Tassone, E. J., Anzaldi, M., Barone, M., Bazzini, C., Bianchi, P. I., Boari, B., Bracco, C., Buonauro, A., Butta, C., Buzzetti, E., Calabria, S., Caradio, F., Carleo, P., Carrabba Maria, D., Castorani, L., Cicco, S., Cimini, C., Colombo, B. M., De Vuono, S., Denegri, A., Del Corso, L., Di Giosia, P., Donnarumma, E., Giorgini, P., Grassi, D., Grembiale, A., Hijazi, D., Iamele, L., Lorusso, G., Marchese, A., Marra, A. M., Miceli, G., Montebianco, A. L., Murgia, G., Naccarato, P., Padula, D., Pattoneri, P., Perego, F., Pesce, P., Petramala, L., Piano, S., Pinto, D., Pinna, M., Pignataro, F. S., Pretti, V., Pucci, G., Salinaro, F., Salzano, A., Santarossa, C., Scarpini, F., Scicali, R., Sirico, D., Suppressa, P., Talia, M., Torres, D., Traversa, M., Vazzana, N., Vecchio Claudia, R., Vettore, E., and Vitale, F.
- Subjects
Liver Cirrhosis ,Male ,Settore MED/09 - Medicina Interna ,030204 cardiovascular system & hematology ,Gastroenterology ,Severity of Illness Index ,cjirrhosis ,ACTIVATION ,0302 clinical medicine ,Risk Factors ,Medicine ,Platelet ,Prospective Studies ,Prospective cohort study ,RISK ,Aged, 80 and over ,medicine.diagnostic_test ,PRO-LIVER ,Platelet, cirrhosis, gastrointestinal bleeding ,ASSOCIATION ,Middle Aged ,Prognosis ,Italy ,030211 gastroenterology & hepatology ,Female ,Gastrointestinal Hemorrhage ,Human ,Adult ,Platelets ,medicine.medical_specialty ,Prognosi ,Liver Cirrhosi ,MEDLINE ,COAGULATION ,gastrointestinal bleeding ,Socio-culturale ,Hemorrhage ,Hepatology ,Follow-Up Studie ,03 medical and health sciences ,Text mining ,Internal medicine ,Severity of illness ,ENDOTOXEMIA ,Pro-Liver Study ,Humans ,HEMOSTASIS ,International Normalized Ratio ,Aged ,Proportional Hazards Models ,Prothrombin time ,Cirrhosi ,Platelet Count, Bleeding, Liver Cirrhosis ,business.industry ,Proportional hazards model ,Platelet Count ,Risk Factor ,cirrhosis ,bleeding ,Thrombocytopenia ,Prospective Studie ,THROMBOSIS ,Platelets, cjirrhosis, bleeding, PRO-LIVER ,Proportional Hazards Model ,Prothrombin Time ,business ,DECOMPENSATED CIRRHOSIS ,Follow-Up Studies - Abstract
OBJECTIVES: Thrombocytopenia is a hallmark for patients with cirrhosis and it is perceived as a risk factor for bleeding events. However, the relationship between platelet count and bleeding is still unclear. METHODS: We investigated the relationship between platelet count and major or clinical relevant nonmajor bleedings during a follow-up of â¼4 years. RESULTS: A total of 280 cirrhotic patients with different degrees of liver disease (67% males; age 64±37 years; 47% ChildâPugh B and C) were followed up for a median of 1,129 (interquartile range: 800â1,498) days yielding 953.12 patient-year of observation. The annual rate of any significant bleeding was 5.45%/year (3.57%/year and 1.89%/year for major and minor bleeding, respectively). Fifty-two (18.6%) patients experienced a major (n=34) or minor (n=18) bleeding event, predominantly from gastrointestinal origin. Platelet counts progressively decreased with the worsening of liver disease and were similar in patients with or without major or minor bleeding: a platelet count â¤50Ã103/μl was detected in 3 (6%) patients with and in 20 (9%) patients without any bleeding event. Conversely, prothrombin time-international normalized ratio was slightly higher in patients with overall or major bleeding. On Cox proportional hazard analysis, only a previous gastrointestinal bleeding (hazard ratio (HR): 1.96; 95% confidence interval: 1.11â3.47; P=0.020) and encephalopathy (HR: 2.05; 95% confidence interval: 1.16â3.62; P=0.013) independently predicted overall bleeding events. CONCLUSIONS: Platelet count does not predict unprovoked major or minor bleeding in cirrhotic patients.
- Published
- 2018
210. A familial case of Dowling–Degos disease on the vulva.
- Author
-
Coco, V., Guerriero, C., Esposito, I., De Vincenzo, R. P., and Peris, K.
- Subjects
- *
GENETIC disorders , *EPIDERMOLYSIS bullosa , *GRIDS (Cartography) , *ACANTHOSIS nigricans , *VULVAR diseases - Abstract
Dowling-Degos disease (DDD) is a rare genodermatosis, which was first described by Dowling and Freudenthal in 1938 and then by Degos and Ossipowski in 1954. GLO:DF2/01dec19:ced13914-fig-0001.jpg PHOTO (COLOR): (a) Dowling-Degos disease of the mother's vulva: multiple hyperpigmented brownish macules showing dark brown to black macules in both solitary and confluent patterns. GLO:DF2/01dec19:ced13914-fig-0002.jpg PHOTO (COLOR): (a) Dowling-Degos disease of the daughter's vulva: the macules were lighter in colour (light brown) and fewer in number than in the mother. [Extracted from the article]
- Published
- 2019
- Full Text
- View/download PDF
211. Peritoneal <scp>HPV‐DNA</scp> test in cervical cancer (PIONEER study): A proof of concept
- Author
-
Simona Marchetti, Nicolò Bizzarri, Gabriella Ferrandina, Barbara Costantini, Giovanni Scambia, Paola Cattani, Carmine Conte, Luigi Pedone Anchora, Francesco Fanfani, Rosa De Vincenzo, Vito Chiantera, Valerio Gallotta, Anna Fagotti, Giuseppe Vizzielli, Salvatore Gueli Alletti, Bizzarri N., Pedone Anchora L., Cattani P., De Vincenzo R., Marchetti S., Conte C., Chiantera V., Gallotta V., Gueli Alletti S., Vizzielli G., Costantini B., Fagotti A., Fanfani F., Scambia G., and Ferrandina G.
- Subjects
Adult ,HPV ,Cancer Research ,medicine.medical_specialty ,Multivariate analysis ,cervical cancer ,genotype ,medicine.medical_treatment ,Uterine Cervical Neoplasms ,prognostic factors ,Gastroenterology ,Human Papillomavirus DNA Tests ,03 medical and health sciences ,Peritoneal cavity ,0302 clinical medicine ,genotypes ,Internal medicine ,Genotype ,medicine ,Humans ,Prospective Studies ,Stage (cooking) ,Peritoneal Cavity ,Cervix ,Aged ,Neoplasm Staging ,Aged, 80 and over ,Cervical cancer ,Human papillomavirus 16 ,Human papillomavirus 18 ,business.industry ,HPV infection ,Middle Aged ,peritoneum ,medicine.disease ,Cervical conization ,infection ,Settore MED/40 - GINECOLOGIA E OSTETRICIA ,medicine.anatomical_structure ,Oncology ,030220 oncology & carcinogenesis ,Female ,business - Abstract
The aim of this study was to investigate the prevalence of peritoneal human papillomavirus (HPV) infection in different clinical cervical cancer (CC) settings, and its association with potential clinical and/or histological factors. This is a single-center, prospective, observational study. Consecutive patients with newly diagnosed or recurrent/persistent CC, between March 2019 and April 2020, were included. A group of patients undergoing surgery for benign gynecological conditions was included as control group. All patients underwent HPV-DNA test in the cervix and in the peritoneal cavity simultaneously at time of surgery. Two-hundred seventy-two patients had cervical and peritoneal HPV test analyzed. Cervical and peritoneal HPV positivity (PHP) was found in 235 (88.0%) and 78 (28.7%) patients, respectively; the prevalence of PHP was 17.7% in early stage, 28.8% in locally advanced cervical cancer (LACC) and 46.6% in the metastatic/persistent/recurrent setting (P = .001). No control patient was found to have peritoneal HPV infection. Higher frequency of PHP was documented in patients with larger tumor size (P = .003), presence of cervical HPV 16/18 genotypes (P
- Published
- 2020
- Full Text
- View/download PDF
212. Il consenso del minore di età tra privacy e contratti
- Author
-
Ettore Battelli, AA. VV., BATTELLI E., VINCENZO R., GATTA L., GAROFOLI R., and Battelli, Ettore
- Subjects
trattamento dati personali, minore di età, consenso digitale, internet - Published
- 2022
213. Protective Role of Conization Before Radical Hysterectomy in Early-Stage Cervical Cancer: A Propensity-Score Matching Study
- Author
-
Valerio Gallotta, Giovanni Scambia, Luigi Pedone Anchora, Matteo Bruno, Anna Fagotti, Giuseppe Vizzielli, Gabriella Ferrandina, Vittoria Carbone, Nithya Ratnavelu, Camilla Fedele, Nicolò Bizzarri, Ali Kucukmetin, Rosa De Vincenzo, Francesco Fanfani, Vito Chiantera, Porfyrios Korompelis, Bizzarri N., Pedone Anchora L., Kucukmetin A., Ratnavelu N., Korompelis P., Carbone V., Fedele C., Bruno M., Vizzielli G., Gallotta V., De Vincenzo R., Chiantera V., Fagotti A., Fanfani F., Ferrandina G., and Scambia G.
- Subjects
medicine.medical_specialty ,Conization ,Uterine Cervical Neoplasms ,Hysterectomy ,03 medical and health sciences ,0302 clinical medicine ,Medicine ,Humans ,Risk factor ,Stage (cooking) ,Radical surgery ,Radical Hysterectomy ,Neoplasm Staging ,Retrospective Studies ,Cervical cancer ,business.industry ,Perioperative ,medicine.disease ,Surgery ,Neoplasm Recurrence ,Settore MED/40 - GINECOLOGIA E OSTETRICIA ,Local ,Oncology ,030220 oncology & carcinogenesis ,Propensity score matching ,030211 gastroenterology & hepatology ,Female ,Neoplasm Recurrence, Local ,business ,Cohort study - Abstract
Purpose: The purpose of this study was to assess the prognostic role and the perioperative outcomes of conization performed before radical hysterectomy in early-stage cervical carcinoma. Methods: This multicenter, retrospective observational cohort study included patients with FIGO 2009stage IB1 cervical carcinoma treated with radical hysterectomy between June 2004 and June 2019. Patients were divided into two groups according to conization before radical surgery. One-to-one case–control matching was used to adjust the baseline characteristics. Results: A total of 332 patients were included after propensity matching (166, 50% in each group). Twenty-four of 166 (14.4%) and 142 of 166 (85.6%) conization patients had negative and positive surgical margins on the conization specimen, respectively. No difference in intra- and postoperative complications was noted between the two groups (p=0.542 and p=0.180, respectively). Patients undergoing conization before radical hysterectomy received less adjuvant treatment (p20 mm and no conization before radical hysterectomy (p=0.011 and p=0.018, respectively). The only independent variable influencing OS was pathologic tumor diameter >20 mm (p=0.020). Conclusions: Conization before radical hysterectomy was associated with improved DFS and lower probability of receiving adjuvant treatment. No difference in perioperative complications and OS was evident. Tumor diameter >20 mm was found to be the only independent risk factor affecting OS in both groups.
- Published
- 2020
214. Development of a Nomogram Predicting the Risk of Persistence/Recurrence of Cervical Dysplasia
- Author
-
Giorgio Bogani, Luca Lalli, Francesco Sopracordevole, Andrea Ciavattini, Alessandro Ghelardi, Tommaso Simoncini, Francesco Plotti, Jvan Casarin, Maurizio Serati, Ciro Pinelli, Alice Bergamini, Barbara Gardella, Andrea Dell’Acqua, Ermelinda Monti, Paolo Vercellini, Innocenza Palaia, Giorgia Perniola, Margherita Fischetti, Giusi Santangelo, Alice Fracassi, Giovanni D’Ippolito, Lorenzo Aguzzoli, Vincenzo Dario Mandato, Luca Giannella, Cono Scaffa, Francesca Falcone, Chiara Borghi, Mario Malzoni, Andrea Giannini, Maria Giovanna Salerno, Viola Liberale, Biagio Contino, Cristina Donfrancesco, Michele Desiato, Anna Myriam Perrone, Giulia Dondi, Pierandrea De Iaco, Simone Ferrero, Giuseppe Sarpietro, Maria G. Matarazzo, Antonio Cianci, Stefano Cianci, Sara Bosio, Simona Ruisi, Lavinia Mosca, Raffaele Tinelli, Rosa De Vincenzo, Gian Franco Zannoni, Gabriella Ferrandina, Marco Petrillo, Giampiero Capobianco, Salvatore Dessiole, Annunziata Carlea, Fulvio Zullo, Barbara Muschiato, Stefano Palomba, Stefano Greggi, Arsenio Spinillo, Fabio Ghezzi, Nicola Colacurci, Roberto Angioli, Pierluigi Benedetti Panici, Ludovico Muzii, Giovanni Scambia, Francesco Raspagliesi, Violante Di Donato, Bogani, G., Lalli, L., Sopracordevole, F., Ciavattini, A., Ghelardi, A., Simoncini, T., Plotti, F., Casarin, J., Serati, M., Pinelli, C., Bergamini, A., Gardella, B., Dell'Acqua, A., Monti, E., Vercellini, P., Palaia, I., Perniola, G., Fischetti, M., Santangelo, G., Fracassi, A., D'Ippolito, G., Aguzzoli, L., Mandato, V. D., Giannella, L., Scaffa, C., Falcone, F., Borghi, C., Malzoni, M., Giannini, A., Salerno, M. G., Liberale, V., Contino, B., Donfrancesco, C., Desiato, M., Perrone, A. M., Dondi, G., De Iaco, P., Ferrero, S., Sarpietro, G., Matarazzo, M. G., Cianci, A., Cianci, S., Bosio, S., Ruisi, S., Mosca, L., Tinelli, R., De Vincenzo, R., Zannoni, G. F., Ferrandina, G., Petrillo, M., Capobianco, G., Dessiole, S., Carlea, A., Zullo, F., Muschiato, B., Palomba, S., Greggi, S., Spinillo, A., Ghezzi, F., Colacurci, N., Angioli, R., Panici, P. B., Muzii, L., Scambia, G., Raspagliesi, F., Di Donato, V., Bogani, Giorgio, Lalli, Luca, Sopracordevole, Francesco, Ciavattini, Andrea, Ghelardi, Alessandro, Simoncini, Tommaso, Plotti, Francesco, Casarin, Jvan, Serati, Maurizio, Pinelli, Ciro, Bergamini, Alice, Gardella, Barbara, Dell'Acqua, Andrea, Monti, Ermelinda, Vercellini, Paolo, Palaia, Innocenza, Perniola, Giorgia, Fischetti, Margherita, Santangelo, Giusi, Fracassi, Alice, D'Ippolito, Giovanni, Aguzzoli, Lorenzo, Mandato, Vincenzo Dario, Giannella, Luca, Scaffa, Cono, Falcone, Francesca, Borghi, Chiara, Malzoni, Mario, Giannini, Andrea, Salerno, Maria Giovanna, Liberale, Viola, Contino, Biagio, Donfrancesco, Cristina, Desiato, Michele, Perrone, Anna Myriam, Dondi, Giulia, De Iaco, Pierandrea, Ferrero, Simone, Sarpietro, Giuseppe, Matarazzo, Maria G, Cianci, Antonio, Cianci, Stefano, Bosio, Sara, Ruisi, Simona, Mosca, Lavinia, Tinelli, Raffaele, De Vincenzo, Rosa, Zannoni, Gian Franco, Ferrandina, Gabriella, Petrillo, Marco, Capobianco, Giampiero, Dessiole, Salvatore, Carlea, Annunziata, Zullo, Fulvio, Muschiato, Barbara, Palomba, Stefano, Greggi, Stefano, Spinillo, Arsenio, Ghezzi, Fabio, Colacurci, Nicola, Angioli, Roberto, Benedetti Panici, Pierluigi, Muzii, Ludovico, Scambia, Giovanni, Raspagliesi, Francesco, and Di Donato, Violante
- Subjects
Pharmacology ,conization ,HPV ,Settore MED/40 - GINECOLOGIA E OSTETRICIA ,recurrence ,Infectious Diseases ,Drug Discovery ,Immunology ,LEEP ,Pharmacology (medical) ,cervical dysplasia - Abstract
Background: Cervical dysplasia persistence/recurrence has a great impact on women’s health and quality of life. In this study, we investigated whether a prognostic nomogram may improve risk assessment after primary conization. Methods: This is a retrospective multi-institutional study based on charts of consecutive patients undergoing conization between 1 January 2010 and 31 December 2014. A nomogram assessing the importance of different variables was built. A cohort of patients treated between 1 January 2015 and 30 June 2016 was used to validate the nomogram. Results: A total of 2966 patients undergoing primary conization were analyzed. The median (range) patient age was 40 (18–89) years. At 5-year of follow-up, 6% of patients (175/2966) had developed a persistent/recurrent cervical dysplasia. Median (range) recurrence-free survival was 18 (5–52) months. Diagnosis of CIN3, presence of HR-HPV types, positive endocervical margins, HPV persistence, and the omission of HPV vaccination after conization increased significantly and independently of the risk of developing cervical dysplasia persistence/recurrence. A nomogram weighting the impact of all variables was built with a C-Index of 0.809. A dataset of 549 patients was used to validate the nomogram, with a C-index of 0.809. Conclusions: The present nomogram represents a useful tool for counseling women about their risk of persistence/recurrence after primary conization. HPV vaccination after conization is associated with a reduced risk of CIN2+.
- Published
- 2022
- Full Text
- View/download PDF
215. Corrigendum to "Nucleosome binding peptide presents laudable biophysical and in vivo effects" [Biomed. Pharmacother. 121 (2020) 109678].
- Author
-
Teles, Kaian, Fernandes, Vinicius, Silva, Isabel, Leite, Manuela, Grisolia, Cesar, Lobbia, Vincenzo R., van Ingen, Hugo, Honorato, Rodrigo, Lopes-de-Oliveira, Paulo, Treptow, Werner, and Santos, Guilherme
- Subjects
- *
CIRCULAR dichroism - Abstract
Fluorescence fish embryo, will be 2.15 Fish embryo Fluorescence Fluorescence blood smear, will be 2.16 Blood Smear Fluorescence (17) In legend figure 5, it says 52 h post fertilization, it should be 52 h post fertilization. [Extracted from the article]
- Published
- 2020
- Full Text
- View/download PDF
216. A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme)
- Author
-
Gerardo Rosati, Francesco Bianco, Antonella Petrillo, Chiara Carlomagno, Guglielmo Nasti, Vincenzo Rosario Iaffaioli, Alessandra Leone, Pasquale Aprea, Vincenza Granata, Carmela Romano, Ciro Gallo, Elisabetta de Lutio di Castelguidone, Paolo Delrio, Piera Maiolino, Gerardo Botti, Mario De Bellis, Elena Di Gennaro, Luigi Aloj, Secondo Lastoria, Orlando Catalano, Maria Carmela Piccirillo, Fabiana Tatangelo, Corradina Caracò, Alessandro Bertolini, Alfredo Budillon, Francesco Izzo, Biagio Pecori, Antonio Avallone, Giovanni Maria Romano, Ernesta Cavalcanti, Gennaro Daniele, Francesco Perrone, Aloj, Luigi [0000-0002-7452-4961], Apollo - University of Cambridge Repository, Avallone, A., Piccirillo, M. C., Aloj, L., Nasti, G., Delrio, P., Izzo, F., Di Gennaro, E., Tatangelo, F., Granata, V., Cavalcanti, E., Maiolino, P., Bianco, F., Aprea, P., De Bellis, M., Pecori, B., Rosati, G., Carlomagno, C., Bertolini, A., Gallo, C., Romano, C., Leone, A., Caraco, C., de Lutio di Castelguidone, E., Daniele, G., Catalano, O., Botti, G., Petrillo, A., Romano, G. M., Iaffaioli, V. R., Lastoria, S., Perrone, F., Budillon, A., Avallone, Antonio, Piccirillo, Maria Carmela, Aloj, Luigi, Nasti, Guglielmo, Delrio, Paolo, Izzo, Francesco, Di Gennaro, Elena, Tatangelo, Fabiana, Granata, Vincenza, Cavalcanti, Ernesta, Maiolino, Piera, Bianco, Francesco, Aprea, Pasquale, De Bellis, Mario, Pecori, Biagio, Rosati, Gerardo, Carlomagno, Chiara, Bertolini, Alessandro, Gallo, Ciro, Romano, Carmela, Leone, Alessandra, Caracò, Corradina, de Lutio di Castelguidone, Elisabetta, Daniele, Gennaro, Catalano, Orlando, Botti, Gerardo, Petrillo, Antonella, Romano, Giovanni M., Iaffaioli, Vincenzo R., Lastoria, Secondo, Perrone, Francesco, and Budillon, Alfredo
- Subjects
0301 basic medicine ,Oncology ,Male ,Vascular Endothelial Growth Factor A ,Cancer Research ,Organoplatinum Compounds ,Colorectal cancer ,Leucovorin ,Phases of clinical research ,Colorectal Neoplasm ,Study Protocol ,0302 clinical medicine ,FOLFOX ,Antineoplastic Combined Chemotherapy Protocols ,Clinical endpoint ,FDG-PET ,Antibodies, Monoclonal ,Middle Aged ,Prognosis ,Oxaliplatin ,Bevacizumab ,030220 oncology & carcinogenesis ,Female ,Fluorouracil ,Colorectal Neoplasms ,medicine.drug ,Human ,Adult ,medicine.medical_specialty ,Prognosi ,Antibodies, Monoclonal, Humanized ,Biomarkers for anti-angiogenic therapy ,Disease-Free Survival ,03 medical and health sciences ,Internal medicine ,medicine ,Genetics ,Humans ,Aged ,Antineoplastic Combined Chemotherapy Protocol ,business.industry ,Organoplatinum Compound ,medicine.disease ,Clinical trial ,Regimen ,030104 developmental biology ,Vessel normalization ,business - Abstract
BACKGROUND: Despite the improvements in diagnosis and treatment, colorectal cancer (CRC) is the second cause of cancer deaths in both sexes. Therefore, research in this field remains of great interest. The approval of bevacizumab, a humanized anti-vascular endothelial growth factor (VEGF) monoclonal antibody, in combination with a fluoropyrimidine-based chemotherapy in the treatment of metastatic CRC has changed the oncology practice in this disease. However, the efficacy of bevacizumab-based treatment, has thus far been rather modest. Efforts are ongoing to understand the better way to combine bevacizumab and chemotherapy, and to identify valid predictive biomarkers of benefit to avoid unnecessary and costly therapy to nonresponder patients. The BRANCH study in high-risk locally advanced rectal cancer patients showed that varying bevacizumab schedule may impact on the feasibility and efficacy of chemo-radiotherapy. METHODS/DESIGN: OBELICS is a multicentre, open-label, randomised phase 3 trial comparing in mCRC patients two treatment arms (1:1): standard concomitant administration of bevacizumab with chemotherapy (mFOLFOX/OXXEL regimen) vs experimental sequential bevacizumab given 4 days before chemotherapy, as first or second treatment line. Primary end point is the objective response rate (ORR) measured according to RECIST criteria. A sample size of 230 patients was calculated allowing reliable assessment in all plausible first-second line case-mix conditions, with a 80% statistical power and 2-sided alpha error of 0.05. Secondary endpoints are progression free-survival (PFS), overall survival (OS), toxicity and quality of life. The evaluation of the potential predictive role of several circulating biomarkers (circulating endothelial cells and progenitors, VEGF and VEGF-R SNPs, cytokines, microRNAs, free circulating DNA) as well as the value of the early [(18)F]-Fluorodeoxyglucose positron emission tomography (FDG-PET) response, are the objectives of the traslational project. DISCUSSION: Overall this study could optimize bevacizumab scheduling in combination with chemotherapy in mCRC patients. Moreover, correlative studies could improve the knowledge of the mechanisms by which bevacizumab enhance chemotherapy effect and could identify early predictors of response. EudraCT Number: 2011-004997-27 TRIAL REGISTRATION: ClinicalTrials.gove number, NCT01718873.
- Published
- 2016
217. Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients
- Author
-
Giulia Amadio, M. Di Stefano, Valeria Masciullo, A. Di Legge, Giovanni Scambia, Giovanni Citterio, Domenica Lorusso, Antonella Pietragalla, Claudio Bordignon, Antonio Lambiase, G. Mangili, M Mantori, R. De Vincenzo, Lorusso, D, Scambia, G, Amadio, G, DI LEGGE, A, Pietragalla, A, DE VINCENZO, R, Masciullo, V, DI STEFANO, M, Mangili, G, Citterio, G, Mantori, M, Lambiase, A, and Bordignon, Claudio
- Subjects
Adult ,Bridged-Ring Compounds ,Cancer Research ,medicine.medical_specialty ,Recombinant Fusion Proteins ,Phases of clinical research ,Platinum Compounds ,Gastroenterology ,doxorubicin ,Disease-Free Survival ,Drug Administration Schedule ,NGR-hTNF ,Interquartile range ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Clinical endpoint ,medicine ,Humans ,Treatment Failure ,Aged ,Ovarian Neoplasms ,Taxane ,vascular targeting agent ,business.industry ,Tumor Necrosis Factor-alpha ,Middle Aged ,Surgery ,Regimen ,Settore MED/40 - GINECOLOGIA E OSTETRICIA ,ovarian cancer ,Oncology ,Quartile ,Tolerability ,Female ,Taxoids ,business ,Translational Therapeutics - Abstract
Background: The NGR-hTNF (asparagine–glycine–arginine–human tumour necrosis factor) is able to promote antitumour immune responses and to improve the intratumoural doxorubicin uptake by selectively damaging tumour blood vessels. Methods: Patients progressing after ⩾1 platinum/taxane-based regimen received NGR-hTNF 0.8 μg m−2 and doxorubicin 60 mg m−2 every 3 weeks. Primary endpoint was a Response Evaluation Criteria in Solid Tumors-defined response rate with a target of more than 6 out of 37 responding patients. Results: A total of 37 patients with platinum-free interval lower than 6 months (PFI
- Published
- 2012
218. Nucleosome binding peptide presents laudable biophysical and in vivo effects.
- Author
-
Teles, Kaian, Fernandes, Vinicius, Silva, Isabel, Leite, Manuela, Grisolia, Cesar, Lobbia, Vincenzo R., van Ingen, Hugo, Honorato, Rodrigo, Lopes-de-Oliveira, Paulo, Treptow, Werner, and Santos, Guilherme
- Subjects
- *
CARRIER proteins , *SURFACE interactions , *CHEMICAL stability , *CHROMATIN , *PEPTIDES - Abstract
• Structure-based calculations on the nucleosome surface interaction shows that NBPeps induce specific atomic fluctuations of the nucleosome structure. • In vitro studies shows that NBPeps may affect the stability of the nucleosome structure. • Cell-based assays shows that the NBPeps may penetrate the cell and localizes at the nuclear environment. • Fish embryo toxicity (FET) test shows that the NBPeps can cause tissue modifications, such as defects in pigmentation and induction of earlier hatching. • H4 peptide shows to be highly specific for targeting the nucleosome, with important effects on the final nucleosome structure and robust in vivo effects. Chromatin state is highly dependent on the nucleosome binding proteins. Herein, we used a multipronged approach employing biophysical and in vivo experiments to characterize the effects of Nucleosome Binding Peptides (NBPeps) on nucleosome and cell activity. We performed a series of structure-based calculations on the nucleosome surface interaction with GMIP1 (a novel NBPep generated in silico), and HMGN2 (nucleosome binding motif of HMGN2), which contains sites that bind DNA and the acid patch, and also LANA and H4pep (nucleosome binding motif of H4 histone tail) that only bind to the acidic patch. Biochemical assays shows that H4pep, but not HMGN2, GMIP1 and LANA, is highly specific for targeting the nucleosome, with important effects on the final nucleosome structure and robust in vivo effects. These findings suggest that NBPeps might have important therapeutic implications and relevance as tools for chromatin investigation. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
219. Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase II study
- Author
-
Vanda Salutari, M. Colangelo, Giovanni Scambia, Gabriella Ferrandina, R. De Vincenzo, Manuela Ludovisi, T. Prantera, Domenica Lorusso, Maria Rosaria Valerio, Ferrandina, G, Ludovisi, M, De Vincenzo, R, Salutari, V, Lorusso, D, Colangelo, M, Prantera, T, Valerio, MR, and Scambia, G
- Subjects
Adult ,medicine.medical_specialty ,Organoplatinum Compounds ,Anemia ,Settore MED/06 - Oncologia Medica ,Ovarian cancer recurrence ,docetaxel, ovarian cancer recurrence, oxaliplatin ,Phases of clinical research ,Docetaxel ,Gastroenterology ,Disease-Free Survival ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Aged ,Ovarian Neoplasms ,Leukopenia ,business.industry ,Hematology ,Middle Aged ,medicine.disease ,Oxaliplatin ,Surgery ,Regimen ,Treatment Outcome ,Oncology ,Toxicity ,Female ,Taxoids ,medicine.symptom ,Neoplasm Recurrence, Local ,Ovarian cancer ,business ,medicine.drug - Abstract
Background A prospective phase II study was conducted to evaluate the efficacy and toxicity of the combination docetaxel (Taxotere) (DTX) and oxaliplatin (OXA) in ovarian cancer patients recurring after a platinum-free interval (PFI) >12 months. Patients and methods DTX, 75 mg/m2, was administered by 60 min i.v. infusion, followed by OXA, 100 mg/m2, given by a 2 h i.v., on day 1 every 21 days. Results From October 2003 to June 2006, 43 ovarian cancer patients were enrolled. Median PFI was 26 months. All patients were available for response evaluation: 17 complete responses and 12 partial responses were registered, for an overall response rate of 67.4%. The median response duration was 10 months. Stable disease was documented in 11 patients (median duration = 5.5 months). The median time to progression and overall survival were 14 and 28 months. A total of 259 courses were administered. Grade 3–4 leukopenia was documented in 32.5% of the patients, while no case of severe anemia and thrombocytopenia was observed. Grade 3–4 neurotoxicity and grade 2 alopecia were observed in 9.3% and 34.9% of cases, respectively. Conclusion DTX/OXA combination is an active regimen with a favorable toxicity profile, for treatment of recurrent platinum-sensitive ovarian cancer patients.
- Published
- 2007
220. Prophylactic HPV vaccination in HPV-related gynecologic cancers: European Society of Gynecological Oncology (ESGO) prevention committee opinion.
- Author
-
Bizzarri N, Kyrgiou M, De Vincenzo R, Zapardiel I, Razumova Z, Taumberger N, Toth I, Theofanakis C, Gultekin M, and Joura EA
- Abstract
Many clinicians recommend that patients diagnosed with HPV-related gynecologic cancers receive prophylactic HPV vaccination at the time of cancer diagnosis or after cancer treatment. In view of the large use of such practice, we aimed to assess the literature evidence supporting the use of prophylactic HPV vaccines after diagnosis or treatment of HPV-related gynecologic cancers. Women who develop HPV-related cervical, vaginal, and vulvar cancers represent a subgroup of patients who may be particularly sensitive to HPV infection and re-acquire infections. The rationale that the use of prophylactic HPV vaccination at the time or after treatment for cervical, vaginal, and vulvar cancers might reduce the risk of future HPV-related diseases might be explained by the data coming from the use of HPV vaccination after treatment of pre-invasive disease; however, the evidence on the use of HPV vaccination in the setting of HPV-related gynecologic cancers is currently absent. In this context, observational and experimental studies document an important drop in effectiveness of HPV vaccination by age. Physicians should be aware of catch-up programs in their countries and should be ready to counsel patients about prophylactic HPV vaccine efficacy according to their age. In general, no evidence exists supporting the use of prophylactic HPV vaccine in patients diagnosed with HPV-related gynecologic cancers; therefore, the European Society of Gynecological Oncology (ESGO) prevention committee opinion is to counsel these patients as any HPV-related non-gynecologic cancer (such as anal or oropharyngeal cancer) and non-cancer patient, suggesting vaccination according to patient's age and prognosis, knowing there is a decrease of efficacy with increasing age. Studies on the use of prophylactic HPV vaccine in patients diagnosed with HPV-related gynecologic cancers are strongly needed., (© 2024 The Author(s). International Journal of Gynecology & Obstetrics published by John Wiley & Sons Ltd on behalf of International Federation of Gynecology and Obstetrics.)
- Published
- 2024
- Full Text
- View/download PDF
221. MRI-based assessment of residual disease after neoadjuvant chemotherapy in pregnant women with cervical cancer.
- Author
-
Russo L, D'Erme L, Bottazzi S, Amerighi A, Dolciami M, Bernardini F, De Vincenzo R, Fanfani F, Scambia G, Sala E, and Gui B
- Subjects
- Humans, Female, Pregnancy, Adult, Retrospective Studies, Chemotherapy, Adjuvant, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Neoplasm, Residual diagnostic imaging, Neoadjuvant Therapy methods, Magnetic Resonance Imaging methods, Uterine Cervical Neoplasms diagnostic imaging, Uterine Cervical Neoplasms drug therapy, Uterine Cervical Neoplasms pathology, Pregnancy Complications, Neoplastic diagnostic imaging, Pregnancy Complications, Neoplastic drug therapy, Pregnancy Complications, Neoplastic pathology, Sensitivity and Specificity
- Abstract
Purpose: This study explores the performance of MRI in detecting residual disease after platinum-based neoadjuvant chemotherapy (NACT) in pregnant cervical cancer (CC) patients, which would serve as a surrogate of treatment response., Methods: In this retrospective single-centre study, consecutive pregnant cervical cancer patients treated with NACT and undergoing MRI examination before and at the end of the therapeutic protocol between 2010 and 2021 were included. Tumour maximum diameter and nodal status were evaluated in MRI at staging and after NACT. Patients exhibiting increased tumor burden post-NACT were excluded. On post-NACT the presence or absence of residual disease was recorded and the MRI diagnostic performance for assessing residual disease was calculated using histopathology at radical hysterectomy as the reference standard., Results: The study included 12 pregnant patients (median age 36 years, 27-42). At post-NACT MRI, residual disease was absent in 2/12 patients (16.7 %) while present in 10/12 (83.3 %). Histopathology was concordant in all patients without MRI residual disease and in 9/10 patients with MRI residual disease, while discordant in 1/10. MRI sensitivity, specificity, positive predictive value, negative predictive and accuracy for detecting residual disease were 100.0 % (95 %CI: 1.00, 1.00), 66.7 % (95 %CI: 0.13, 1.00), 90 % (95 %CI: 0.71, 1.00), 100 % (95 %CI: 1.00, 1.00), and 91.7 % (95 %CI: 0.76, 1.00) respectively (p = 0.045)., Conclusions: This study suggests that MRI has good diagnostic performance to detect residual disease after NACT in pregnant CC patients, and potentially assess response to treatment in this setting., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024. Published by Elsevier B.V.)
- Published
- 2024
- Full Text
- View/download PDF
222. Peri-procedural anesthesia and patient pain experience in pulmonary vein isolation by means of very high-power short-duration radiofrequency ablation.
- Author
-
Sara P, Teresa S, Assunta I, Giorgio S, Vincenzo S, Alberto A, Gergana S, Mariano SA, Giovanni M, Vincenzo R, Alessia A, Riccardo R, Di Candia CD, Infusino T, Micillo M, Antonio S, Francesco S, and Giuseppe S
- Abstract
Background: Very high-power short-duration (vHPSD) temperature-controlled radiofrequency ablation (vHPSD) may reduce ablation times and improve patient tolerability, permitting pulmonary vein (PV) isolation under mild conscious sedation. We evaluated of the anesthetic drugs use and patients' pain experience during vHPSD PV isolation., Methods: Fifty-eight patients, with paroxysmal and persistent atrial fibrillation (AF), treated with QDot Micro catheter and vHPSD (90 w for 4 s) (vHPSD group), were compared with the last 33 patients treated with a surround flow contact force-sensing catheter guided by the ablation index (450 anteriorly at 50 W, 330 posteriorly at 40 W) (AI group). Anesthetic drugs use was compared as well as pain experience, measured using a 0-10 scale., Results: All PVs were acutely isolated. Procedural time (78 ± 10 min vs 84 ± 12 min, p = 0.012), fluoroscopy time (369 ± 139 s vs 441 ± 172 s, p = 0.03), and RF time in the vHPSD group (8.3 ± 2.1 min) were shorter than in the AI group (25 ± 11 min, p < 0.001). Only 4 patients experienced an access site-related vascular complication (groin hematoma). Midazolam was required in 36 (62%) vHPSD group patients vs 31 (94%) AI group patients (p < 0.001). Fentanyl was required in 4 (7%) vHPSD group patients vs 25 (76%) AI group patients (p < 0.001). No patients required general anesthesia. Twenty-two (38%) vHPSD group patients underwent PV isolation without any anesthetic drug. Pain experience was significantly lower in vHPSD group (4.9 ± 2 vs 6.6 ± 1.8, p < 0.001)., Conclusions: vHPSD radiofrequency ablation for PVI can be performed under conscious sedation using only benzodiazepine in most of patients without compromising patient pain experience., (© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
223. HPV-related lesions after hysterectomy for high-grade cervical intraepithelial neoplasia and early-stage cervical cancer: A focus on the potential role of vaccination.
- Author
-
Bogani G, Sopracordevole F, Ciavattini A, Ghelardi A, Vizza E, Vercellini P, Casarin J, Pinelli C, Ghezzi F, De Vincenzo R, Di Donato V, Golia D'augè T, Giannini A, Sorbi F, Petrillo M, Capobianco G, Vizzielli G, Restaino S, Cianci S, Scambia G, and Raspagliesi F
- Subjects
- Humans, Female, Retrospective Studies, Prospective Studies, Vaccination, Hysterectomy adverse effects, Papillomaviridae, Uterine Cervical Neoplasms prevention & control, Uterine Cervical Neoplasms surgery, Uterine Cervical Neoplasms diagnosis, Papillomavirus Infections complications, Papillomavirus Infections prevention & control, Uterine Cervical Dysplasia diagnosis, Uterine Cervical Dysplasia pathology, Uterine Cervical Dysplasia surgery
- Abstract
Objective: To date, no data supports the execution of vaccination after hysterectomy for high-grade cervical intraepithelial neoplasia (CIN2+) and early-stage cervical cancer. We aim to evaluate the potential effect of vaccination after hysterectomy for high-grade cervical intraepithelial neoplasia and early-stage cervical cancer., Methods: This is a multi-center retrospective study evaluating data of women who develop lower genital tract dysplasia (including anal, vulvar and vaginal intra-epithelial neoplasia) after having hysterectomy for CIN2+ and FIGO stage IA1- IB1 cervical cancer., Results: Overall, charts for 77 patients who developed lower genital tract dysplasia were collected. The study population included 62 (80.5%) and 15 (19.5%) patients with CIN2+ and early-stage cervical cancer, respectively. The median (range) time between hysterectomy and diagnosis of develop lower genital tract dysplasia was 38 (range, 14-62) months. HPV types covered by the nonavalent HPV vaccination would potentially cover 94.8% of the development of lower genital tract dysplasia. Restricting the analysis to the 18 patients with available HPV data at the time of hysterectomy, the beneficial effect of nonvalent vaccination was 89%. However, considering that patients with persistent HPV types (with the same HPV types at the time of hysterectomy and who developed lower genital tract dysplasia) would not benefit from vaccination, we estimated the potential protective effect of vaccination to be 67% (12 out of 18 patients; four patients had a persistent infection for the same HPV type(s))., Conclusions: Our retrospective analysis supported the adoption of HPV vaccination in patients having treatment for HPV-related disease. Even in the absence of the uterine cervix, HPV vaccination would protect against develop lower genital tract dysplasia. Further prospective studies have to confirm our preliminary research., Competing Interests: Declaration of conflicting interestsThe authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
- Published
- 2024
- Full Text
- View/download PDF
224. Long-Term Follow-Up Outcomes in Women with In Situ/Microinvasive Adenocarcinoma of the Uterine Cervix Undergoing Conservative Treatment-Cervical Adenocarcinoma Study Group Italian Society of Colposcopy and Cervico-Vaginal Pathology.
- Author
-
Giannella L, Delli Carpini G, Di Giuseppe J, Grelloni C, Bogani G, Dri M, Sopracordevole F, Clemente N, Giorda G, De Vincenzo R, Evangelista MT, Gardella B, Dominoni M, Monti E, Alessi C, Alessandrini L, Guerriero A, Pagan A, Caretto M, Ghelardi A, Amadori A, Origoni M, Barbero M, Raspagliesi F, Simoncini T, Vercellini P, Spinillo A, Scambia G, and Ciavattini A
- Abstract
Objective: The present study aimed to assess long-term follow-up outcomes in women with in situ/microinvasive adenocarcinoma (AC) of the uterine cervix treated conservatively., Methods: Retrospective multi-institutional study including women with early glandular lesions and 5-year follow-up undergoing fertility-sparing treatment. Independent variables associated with recurrence were evaluated. Logistic regression analysis and Kaplan-Meier survival analysis with Logrank test were performed., Results: Of 269 women diagnosed with in situ/microinvasive AC, 127 participants underwent conservative treatment. During follow-up, recurrences were found in nine women (7.1%). The only factor associated with recurrence during follow-up was positive high-risk Human Papillomavirus (hr-HPV) testing (odds ratio 6.21, confidence interval 1.47-26.08, p = 0.012). HPV positivity in follow-up showed a recurrence rate of 21.7% against 3.8% in patients who were HPV-negative ( p = 0.002, Logrank test). Among women with negative high-risk HPV tests in follow-up, recurrences occurred in 20.0% of non-usual-type histology vs. 2.1% of usual-type cases ( p = 0.005)., Conclusion: HPV testing in follow-up is of pivotal importance in women with early glandular lesions undergoing conservative treatment, given its recurrence predictive value. However, women who are high-risk HPV-negative in follow-up with non-usual-type histopathology may represent a sub-population at increased risk of recurrences. Further studies should confirm these findings.
- Published
- 2024
- Full Text
- View/download PDF
225. Oriented display of HIV-1 Env trimers by a novel coupling strategy enhances B cell activation and phagocytosis.
- Author
-
Di Vincenzo R, Beutel J, Arnold P, Wang Y, Damm D, Tannig P, Lux A, Temchura V, Eichler J, and Überla K
- Subjects
- Humans, HIV Antibodies, Antibodies, Neutralizing, Peptides, Phagocytosis, HIV-1, HIV Seropositivity
- Abstract
Introduction: Conformationally stabilized Env trimers have been developed as antigens for the induction of neutralizing antibodies against HIV-1. However, the non-glycosylated immunodominant base of these soluble antigens may compete with the neutralizing antibody response. This has prompted attempts to couple Env trimers to organic or inorganic nanoparticles with the base facing towards the carrier. Such a site-directed coupling could not only occlude the base of the trimer, but also enhance B cell activation by repetitive display., Methods: To explore the effect of an ordered display of HIV-1 Env on microspheres on the activation of Env-specific B cells we used Bind&Bite, a novel covalent coupling approach for conformationally sensitive antigens based on heterodimeric coiled-coil peptides. By engineering a trimeric HIV-1 Env protein with a basic 21-aa peptide (Peptide K) extension at the C-terminus, we were able to covalently biotinylate the antigen in a site-directed fashion using an acidic complementary peptide (Peptide E) bearing a reactive site and a biotin molecule. This allowed us to load our antigen onto streptavidin beads in an oriented manner., Results: Microspheres coated with HIV-1 Env through our Bind&Bite system showed i) enhanced binding by conformational anti-HIV Env broadly neutralizing antibodies (bNAbs), ii) reduced binding activity by antibodies directed towards the base of Env, iii) higher Env-specific B cell activation, and iv) were taken-up more efficiently after opsonization compared to beads presenting HIV-1 Env in an undirected orientation., Discussion: In comparison to site-directed biotinylation via the Avi-tag, Bind&Bite, offers greater flexibility with regard to alternative covalent protein modifications, allowing selective modification of multiple proteins via orthogonal coiled-coil peptide pairs. Thus, the Bind&Bite coupling approach via peptide K and peptide E described in this study offers a valuable tool for nanoparticle vaccine design where surface conjugation of correctly folded antigens is required., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Di Vincenzo, Beutel, Arnold, Wang, Damm, Tannig, Lux, Temchura, Eichler and Überla.)
- Published
- 2024
- Full Text
- View/download PDF
226. Antigen-dependent modulation of immune responses to antigen-Fc fusion proteins by Fc-effector functions.
- Author
-
Richel E, Wagner JT, Klessing S, Di Vincenzo R, Temchura V, and Überla K
- Subjects
- Animals, Mice, HIV Antibodies, Immunization, Immunity, Humoral, Immunoglobulin Fc Fragments genetics, Vaccines, DNA, HIV-1
- Abstract
Background: Fc-fusion proteins have been successfully developed for therapeutic purposes, but are also a promising platform for the fast generation and purification of immunogens capable of inducing strong humoral immune responses in preclinical immunization studies. As the Fc-portion of immunoglobulins fused to an antigen confers functional properties of the parental antibody, such as dimerization, binding to Fc-receptors and complement activation, several studies reported that Fc-fusion proteins elicit stronger antigen-specific antibody responses than the unfused antigen. However, dimerization or half-life extension of an antigen have also been described to enhance immunogenicity., Methods: To explore the role of Fc-effector functions for the immunogenicity of fusions proteins of viral glycoproteins and Fc fragments, the HIV-1 gp120 and the RBD of SARS-CoV-2 were fused to the wild type muIgG2a Fc fragment or mutants with impaired (LALA-PG) or improved (GASDIE) Fc-effector functions., Results: Immunization of BALB/c mice with DNA vaccines encoding gp120 - Fc LALA-PG induced significantly higher antigen-specific antibody responses than gp120 - Fc WT and GASDIE. In contrast, immunization with DNA vaccines encoding the RBD fused to the same Fc mutants, resulted in comparable anti-RBD antibody levels and similar neutralization activity against several SARS-CoV-2 variants., Conclusion: Depending on the antigen, Fc-effector functions either do not modulate or suppress the immunogenicity of DNA vaccines encoding Fc-antigen fusion proteins., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Richel, Wagner, Klessing, Di Vincenzo, Temchura and Überla.)
- Published
- 2023
- Full Text
- View/download PDF
227. Bind&Bite: covalently stabilized heterodimeric coiled-coil peptides for the site-selective, cysteine-free chemical modification of proteins.
- Author
-
Beutel J, Tannig P, Di Vincenzo R, Schumacher T, Überla K, and Eichler J
- Abstract
Ensuring site-selectivity in covalent chemical modification of proteins is one of the major challenges in chemical biology and related biomedical disciplines. Most current strategies either utilize the selectivity of proteases, or are based on reactions involving the thiol groups of cysteine residues. We have modified a pair of heterodimeric coiled-coil peptides to enable the selective covalent stabilization of the dimer without using enzymes or cysteine moieties. Fusion of one peptide to the protein of interest, in combination with linking the desired chemical modification to the complementary peptide, facilitates stable, regio-selective attachment of the chemical moiety to the protein, through the formation of the covalently stabilized coiled-coil. This ligation method, which is based on the formation of isoeptide and squaramide bonds, respectively, between the coiled-coil peptides, was successfully used to selectively modify the HIV-1 envelope glycoprotein. Covalent stabilization of the coiled-coil also facilitated truncation of the peptides by one heptad sequence. Furthermore, selective addressing of individual positions of the peptides enabled the generation of mutually selective coiled-coils. The established method, termed Bind&Bite, can be expected to be beneficial for a range of biotechnological and biomedical applications, in which chemical moieties need to be stably attached to proteins in a site-selective fashion., Competing Interests: J. B. and T. S. are employees of Institut Virion-Serion GmbH. P. T., R. D. V., K. Ü. and J. E. declare no conflict of interest., (This journal is © The Royal Society of Chemistry.)
- Published
- 2023
- Full Text
- View/download PDF
228. Human papillomavirus (HPV) vaccination: a call for action in Italy.
- Author
-
Bogani G, Ghelardi A, Sopracordevole F, Annoni M, Ciavattini A, Giannella L, De Vincenzo R, Cattani P, Barbero M, Vercellini P, Raspagliesi F, Bonanni P, and Scambia G
- Subjects
- Italy, Humans, Vaccine Efficacy, Immunization Schedule, Papillomavirus Vaccines adverse effects, Papillomavirus Vaccines therapeutic use, Papillomavirus Infections prevention & control, Vaccination Coverage statistics & numerical data, Vaccination Coverage trends
- Abstract
Human papillomavirus (HPV) is the most common sexually transmitted infection. The implementation of primary prevention aims to reduce the burden of HPV infection and HPV-related disease. However, HPV-related diseases are still a concern, even in high-income countries. Approximately 570 000 new cervical cancer cases are diagnosed in Italy every year. Prophylactic HPV vaccines have been developed to minimize the spread of HPV. Growing evidence supports the administration of HPV vaccines (even just one dose) in reducing the prevalence of HPV infection and HPV-related disease including cancers. HPV vaccines are characterized by a high level of efficacy (>95%) in women who are naïve to HPV; however, they do not increase clearance in patients with ongoing HPV infection. With more than 200 million doses administered to date, HPV vaccines are considered to be safe and effective at preventing HPV-related infections and cancers. In this review we aim to review the current evidence regarding HPV vaccination and to describe trends in HPV vaccination coverage in Italy. In Italy, vaccination against HPV has been included in the National Immunization Plan (NIP) since 2007-2008. Using data abstracted from the Italian Ministry of Health, we analyzed changes in HPV vaccination coverage. We observed that HPV vaccines are underutilized and coverage rates are decreasing. Looking at the target population (females and males aged 11-12 years) in Italy, a decrease in coverage rates was observed. A call for action, improved HPV awareness, and education are the key elements to enhance the widespread adoption of HPV vaccination., Competing Interests: Competing interests: None declared., (© IGCS and ESGO 2023. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2023
- Full Text
- View/download PDF
229. Deciphering clinical significance of BCL11A isoforms and protein expression roles in triple-negative breast cancer subtype.
- Author
-
Angius A, Pira G, Cossu-Rocca P, Sotgiu G, Saderi L, Muroni MR, Virdis P, Piras D, Vincenzo R, Carru C, Coradduzza D, Uras MG, Cottu P, Fancellu A, Orrù S, Uva P, and De Miglio MR
- Subjects
- Humans, Female, Clinical Relevance, Breast pathology, Transcription Factors, Immunohistochemistry, Prognosis, Repressor Proteins genetics, Triple Negative Breast Neoplasms pathology, Breast Neoplasms pathology
- Abstract
Purpose: Triple negative breast cancer (TNBC) is an aggressive clinical tumor, accounting for about 25% of breast cancer (BC) related deaths. Chemotherapy is the only therapeutic option to treat TNBC, hence a detailed understanding of the biology and its categorization is required. To investigate the clinical relevance of BCL11A in TNBC subtype, we focused on gene and protein expression and its mutational status in a large cohort of this molecular subtype., Methods: Gene expression profiling of BCL11A and its isoforms (BCL11A-XL, BCL11A-L and BCL11A-S) has been determined in Luminal A, Luminal B, HER2-enriched and TNBC subtypes. BCL11A protein expression has been analyzed by immunohistochemistry (IHC) and its mutational status by Sanger sequencing., Results: In our study, BCL11A was significantly overexpressed in TNBC both at transcriptional and translational levels compared to other BC molecular subtypes. A total of 404 TNBCs were selected and examined showing a high prevalence of BCL11A-XL (37.3%) and BCL11A-L (31.4%) isoform expression in TNBC, associated with a 26% of BCL11A protein expression levels. BCL11A protein expression predicts scarce LIV (HR = 0.52; 95% CI, 0.29-0.92, P = 0.03) and AR downregulation (HR = 0.37; 95% CI, 0.16-0.88; P = 0.02), as well as a higher proliferative index in TNBC cells. BCL11A-L expression is associated with more aggressive TNBC histological types, such as medullary and metaplastic carcinoma., Conclusion: Our finding showed that BCL11A protein expression acts as an unfavorable prognostic factor in TNBC patients, especially in non luminal TNBCs subgroups. These results may yield a better treatment strategy by providing a new parameter for TNBC classification., (© 2022. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
230. Colposcopy Accuracy and Diagnostic Performance: A Quality Control and Quality Assurance Survey in Italian Tertiary-Level Teaching and Academic Institutions-The Italian Society of Colposcopy and Cervico-Vaginal Pathology (SICPCV).
- Author
-
Origoni M, Cantatore F, Sopracordevole F, Clemente N, Spinillo A, Gardella B, De Vincenzo R, Ricci C, Landoni F, Di Meo ML, Ciavattini A, Di Giuseppe J, Preti E, Iacobone AD, Carriero C, Dellino M, Capodanno M, Perino A, Miglioli C, Insolia L, Barbero M, and Candiani M
- Abstract
Quality Control (QC) and Quality Assurance (QA) principles are essential for effective cervical cancer prevention. Being a crucial diagnostic step, colposcopy's sensitivity and specificity improvements are strongly advocated worldwide since inter- and intra-observer differences are the main limiting factors. The objective of the present study was the evaluation of colposcopy accuracy through the results of a QC/QA assessment from a survey in Italian tertiary-level academic and teaching hospitals. A web-based, user-friendly platform based on 100 colposcopic digital images was forwarded to colposcopists with different levels of experience. Seventy-three participants were asked to identify colposcopic patterns, provide personal impressions, and indicate the correct clinical practice. The data were correlated with a panel of experts' evaluation and with the clinical/pathological data of the cases. Overall sensitivity and specificity with the threshold of CIN2+ accounted for 73.7% and 87.7%, respectively, with minor differences between senior and junior candidates. Identification and interpretation of colposcopic patterns showed full agreement with the experts' panel, ranging from 50% to 82%, in some instances with better results from junior colposcopists. Colposcopic impressions correlated with a 20% underestimation of CIN2+ lesions, with no differences linked to level of experience. Our results demonstrate the good diagnostic performance of colposcopy and the need for improving accuracy through QC assessments and adhesion to standard requirements and recommendations.
- Published
- 2023
- Full Text
- View/download PDF
231. Outcomes of High-Grade Cervical Dysplasia with Positive Margins and HPV Persistence after Cervical Conization.
- Author
-
Giannini A, Di Donato V, Sopracordevole F, Ciavattini A, Ghelardi A, Vizza E, D'Oria O, Simoncini T, Plotti F, Casarin J, Golia D'Augè T, Cuccu I, Serati M, Pinelli C, Bergamini A, Gardella B, Dell'Acqua A, Monti E, Vercellini P, D'Ippolito G, Aguzzoli L, Mandato VD, Giannella L, Scaffa C, Ditto A, Falcone F, Borghi C, Malzoni M, Di Giovanni A, Salerno MG, Liberale V, Contino B, Donfrancesco C, Desiato M, Perrone AM, De Iaco P, Ferrero S, Sarpietro G, Matarazzo MG, Cianci A, Cianci S, Bosio S, Ruisi S, Mosca L, Tinelli R, De Vincenzo R, Zannoni GF, Ferrandina G, Petrillo M, Capobianco G, Carlea A, Zullo F, Muschiato B, Palomba S, Greggi S, Spinillo A, Ghezzi F, Colacurci N, Angioli R, Benedetti Panici P, Muzii L, Scambia G, Raspagliesi F, and Bogani G
- Abstract
The objective of this work is to assess the 5-year outcomes of patients undergoing conization for high-grade cervical lesions that simultaneously present as risk factors in the persistence of HPV infection and the positivity of surgical resection margins. This is a retrospective study evaluating patients undergoing conization for high-grade cervical lesions. All patients included had both positive surgical margins and experienced HPV persistence at 6 months. Associations were evaluated with Cox proportional hazard regression and summarized using hazard ratio (HR). The charts of 2966 patients undergoing conization were reviewed. Among the whole population, 163 (5.5%) patients met the inclusion criteria, being at high risk due to the presence of positive surgical margins and experiencing HPV persistence. Of 163 patients included, 17 (10.4%) patients developed a CIN2+ recurrence during the 5-year follow-up. Via univariate analyses, diagnosis of CIN3 instead of CIN2 (HR: 4.88 (95%CI: 1.10, 12.41); p = 0.035) and positive endocervical instead of ectocervical margins (HR: 6.44 (95%CI: 2.80, 9.65); p < 0.001) were associated with increased risk of persistence/recurrence. Via multivariate analyses, only positive endocervical instead of ectocervical margins (HR: 4.56 (95%CI: 1.23, 7.95); p = 0.021) were associated with worse outcomes. In this high-risk group, positive endocervical margins is the main risk factor predicting 5-year recurrence.
- Published
- 2023
- Full Text
- View/download PDF
232. Monitoring the activities of Italian colposcopy clinics before and during the COVID-19 pandemic.
- Author
-
Delli Carpini G, Giorgi Rossi P, Giannella L, Di Giuseppe J, Clemente N, Sopracordevole F, Barbero M, Bogani G, De Vincenzo R, Origoni M, Cantatore F, Gardella B, Dominoni M, Monti E, Liverani CA, Viscardi A, Pagan A, Amadori A, Alessi C, Andolfatto M, Cattani P, Pieralli A, Stevenazzi G, and Ciavattini A
- Subjects
- Pregnancy, Humans, Female, Colposcopy, Pandemics prevention & control, Retrospective Studies, Ambulatory Care Facilities, Uterine Cervical Dysplasia pathology, Uterine Cervical Neoplasms epidemiology, Uterine Cervical Neoplasms surgery, Uterine Cervical Neoplasms diagnosis, COVID-19 epidemiology
- Abstract
Objective: To evaluate the impact of healthcare reorganization during the severe acute respiratory syndrome coronavirus 2 pandemic on Italian colposcopy clinic activities, focusing on cervical excision procedures, follow-ups for conservative management of low-grade lesions, and follow-ups post cervical excision., Methods: Retrospective study conducted in 14 Italian colposcopy clinics. The number and clinical characteristics of cervical excisions, follow-ups for conservative management of low-grade lesions, and follow-ups after cervical excision were compared between the period March 1, 2019 to February 29, 2020 (pre-pandemic) and March 1, 2020 to February 28, 2021 (pandemic) with a Poisson regression analysis., Results: In the pandemic period, the number of cervical excisions was reduced by 8.8% (95% confidence interval [CI]=-15.6% to -2%; p=0.011). Excisions were less frequently performed in the operating room (-35.1%; 95% CI=-47.6% to -22.6%; p<0.001), the number of patients from spontaneous screening was reduced by -14.0% (95% CI=-23.4% to -4.6%; p=0.003), and the CO2-laser technique was used less frequently (-30%; 95% CI=-45.1% to -15.0%; p<0.001). As compared to the pre-pandemic period, the number of follow-ups for conservative management of low-grade lesions was reduced by -26.7% (95% CI=-39.0% to -14.4%; p<0.001), and the follow-up appointments after cervical excision were reduced by -51.0% (95% CI=-58.1% to -43.9%; p<0.001)., Conclusion: The most significant impact of the healthcare reorganization during the coronavirus disease 2019 pandemic was on follow-ups after cervical excision. The resumption of disrupted activities should follow a risk-based prioritization, starting from women in follow-up after cervical excision. It is advisable that the trend of performing cervical excision as an outpatient procedure is maintained in the post-pandemic period., Competing Interests: No potential conflict of interest relevant to this article was reported., (© 2023. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology.)
- Published
- 2023
- Full Text
- View/download PDF
233. Neoadjuvant Chemotherapy in Pregnant Patients with Cervical Cancer: A Monocentric Retrospective Study.
- Author
-
Bernardini F, Ferrandina G, Ricci C, Fagotti A, Fanfani F, Cavaliere AF, Gui B, Scambia G, and De Vincenzo R
- Subjects
- Child, Female, Humans, Hysterectomy, Infant, Newborn, Neoadjuvant Therapy, Pregnancy, Retrospective Studies, Carcinoma, Squamous Cell pathology, Uterine Cervical Neoplasms drug therapy, Uterine Cervical Neoplasms pathology, Uterine Cervical Neoplasms surgery
- Abstract
Background: To date, little and discordant data still exists on the management of cervical cancer (CC) during pregnancy. In this paper, we report our experience of the treatment of these patients analyzing the oncologic, obstetric, and neonatal outcomes., Methods: Between January 2010 and December 2021, 13 patients were diagnosed with CC during pregnancy. All patients underwent platinum-based neoadjuvant chemotherapy (NACT) and 11/13 patients underwent a cesarean radical hysterectomy (CRH)., Results: All 13 patients were diagnosed with squamous-cell carcinoma, FIGO-2018 stage between IB2-IIIC1. The majority of patients had a partial (61.5%) or complete (15.4%) response to NACT. Most patients had a regular course of pregnancy and the obstetric complications observed were gestational diabetes mellitus in 23.1% and IUGR in 15.4% of cases. CRH was performed in the absence of major complications. Only 2 patients (15.4%) had disease recurrence and only 1 patient (7.7%) died of disease. All children are currently healthy. At birth, we observed mainly prematurity-related complications (38.5% respiratory distress syndrome and 7.7% neonatal jaundice) and only a case of congenital malformation (hypospadias). In our pediatric population, we reported a case of malignancy (acute myeloid leukemia)., Conclusion: NACT seems to be safe and efficacious in controlling tumor burden during pregnancy. CRH following NACT appears to be feasible, avoiding repeated surgery and treatment delays. This approach is also reasonably safe from a maternal, obstetric, and neonatal point of view.
- Published
- 2022
- Full Text
- View/download PDF
234. CD9 and ITGA3 are regulated during HIV-1 infection in macrophages to support viral replication.
- Author
-
Kruize Z, Cobos Jiménez V, Martinez FO, Di Vincenzo R, van Dort KA, van Nuenen AC, Booiman T, and Kootstra NA
- Subjects
- Gene Expression Profiling, Humans, Integrin alpha3 genetics, Macrophages metabolism, Tetraspanin 29 genetics, Virus Release physiology, HIV-1 physiology, Integrin alpha3 metabolism, Macrophages virology, Tetraspanin 29 metabolism, Virus Replication physiology
- Abstract
Monocytes/macrophages are important target cells for HIV-1. Here, we investigated whether HIV-1 induces changes in the macrophage gene expression profile to support viral replication. We observed that the macrophage gene expression profiles dramatically changed upon HIV-1 infection. The majority of the HIV-1 regulated genes were also differentially expressed in M2a macrophages. The biological functions associated with the HIV-1 induced gene expression profile in macrophages were mainly related to inflammatory responses. CD9 and ITGA3 were among the top genes upregulated upon HIV-1 infection. We showed that these genes support viral replication and that downregulation of these genes decreased HIV-1 replication in macrophages. Here we showed that HIV-1 infection of macrophages induces a gene expression profile that may dampen inflammatory responses. CD9 and ITGA3 were among the top genes regulated by HIV-1 and were shown to support viral production most likely at the level of viral budding and release., (Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
235. Are We Facing a New Colposcopic Practice in the HPV Vaccination Era? Opportunities, Challenges, and New Perspectives.
- Author
-
Lukic A, De Vincenzo R, Ciavattini A, Ricci C, Senatori R, Ruscito I, and Frega A
- Abstract
The combination of primary and secondary prevention has already influenced the colposcopic practice by reduction in HPV (human papillomavirus) vaccine-type HSIL (HIGH-GRADE SIL), colposcopy referral numbers, colposcopic positive predictive value (PPV) for CIN2+, and by modification of referral pattern, colposcopic performance, and procedures. Different strategies, both isolated and combined, have been proposed in order to maintain the diagnostic accuracy of colposcopy: patient risk stratification based on immediate or future risk of CIN3+ or on HPV genotyping after a positive screening test. Data are needed to support alternative colposcopic strategies based on vaccination status and on the application of artificial intelligence where the patient's risk stratification is implicit in precision medicine which involves the transition from an operator-dependent morphology-based to a less-operator dependent, more biomolecular management. The patient's risk stratification based on any combination of "history" and "test results" to decrease colposcopy workload further reduce colposcopic and histologic morphological approaches, while adding genotyping to the risk stratification paradigm means less cytologic morphologic diagnosis. In Italy, there is a strong colposcopic tradition and there is currently no immediate need to reduce the number of colposcopies. Instead, there is a need for more accredited colposcopists to maintain the diagnostic accuracy of colposcopy in the vaccination era.
- Published
- 2021
- Full Text
- View/download PDF
236. The role of MRI in cervical cancer > 2 cm (FIGO stage IB2-IIA1) conservatively treated with neoadjuvant chemotherapy followed by conization: a pilot study.
- Author
-
Russo L, Gui B, Miccò M, Panico C, De Vincenzo R, Fanfani F, Scambia G, and Manfredi R
- Subjects
- Adult, Chemotherapy, Adjuvant, Female, Humans, Neoadjuvant Therapy, Neoplasm Staging, Pilot Projects, Prospective Studies, Tumor Burden, Uterine Cervical Neoplasms pathology, Uterine Cervical Neoplasms surgery, Young Adult, Conization, Conservative Treatment, Magnetic Resonance Imaging, Uterine Cervical Neoplasms diagnostic imaging, Uterine Cervical Neoplasms drug therapy
- Abstract
Introduction: MRI is very accurate in selecting young women with cervical cancer for fertility-sparing surgery (FSS), in particular radical hysterectomy (RH). In order to improve obstetrical outcomes, neoadjuvant chemotherapy (NACT) followed by cold knife conization (CKC) has been proposed as alternative technique., Objective: To investigate the role of MRI in evaluation of response to treatment after neoadjuvant chemotherapy (NACT), followed by CKC, in patients with cervical cancer FIGO stage IB2-IIA1 with tumor size 2 - 4 cm, desiring to preserve their fertility., Methods: 13 young women (23-36 years old) with cervical cancer stage IB2-IIA1 desiring to preserve their fertility were included. Tumor diameter at baseline and after treatment was detected on 1.5 T MRI. Treatment response was assessed according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and then compared to histopathology result., Results: MRI correctly assessed 11 out of 13 cases, according to RECIST 1.1, compared to histopathology. Among these 7 patients with partial response (PR), 2 cases of CR, 1 SD and 1 PD with persistence or enlargement of primary tumor., Conclusion: Our pilot study supports the usefulness of MRI in assessment of treatment response after NACT, followed by CKC., Trial Registration Number: ClinicalTrials.gov: NCT02323841., (© 2021. The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
237. HPV Vaccination in Women Treated for Cervical Intraepithelial Neoplasia: A Budget Impact Analysis.
- Author
-
Basile M, Calabrò GE, Ghelardi A, Ricciardi R, De Vincenzo R, and Cicchetti A
- Abstract
Human Papillomavirus (HPV) is the most common sexually transmitted infection. Its progression is related to the development of malignant lesions, particularly cervical intraepithelial neoplasias (CINs). CINs correlate with a higher risk of premature births, and their excisional and ablative treatment further increases this risk in pregnant women. These complications are also correlated with higher healthcare costs for their management. In Italy, more than 26,000 new cases of CINs are estimated to occur yearly and their economic burden is significant. Therefore, the management of these conditions is a public health priority. Since HPV vaccination is associated with a reduced risk of relapse in women surgically treated for HPV-related injuries, we estimated the economic impact of extending HPV vaccination to this target population. This strategy would result in a significant reduction in the general costs of managing these women, resulting in an overall saving for the Italian Health Service of €155,596.38 in 5 years. This lower cost is due not only to the reduced incidence of CINs following vaccination, but also to the lower occurrence of preterm births. Extending HPV vaccination to this target population as part of a care path to be offered to women treated for HPV injuries is therefore desirable.
- Published
- 2021
- Full Text
- View/download PDF
238. Protective Role of Conization Before Radical Hysterectomy in Early-Stage Cervical Cancer: A Propensity-Score Matching Study.
- Author
-
Bizzarri N, Pedone Anchora L, Kucukmetin A, Ratnavelu N, Korompelis P, Carbone V, Fedele C, Bruno M, Vizzielli G, Gallotta V, De Vincenzo R, Chiantera V, Fagotti A, Fanfani F, Ferrandina G, and Scambia G
- Subjects
- Female, Humans, Hysterectomy, Neoplasm Recurrence, Local pathology, Neoplasm Staging, Retrospective Studies, Conization, Uterine Cervical Neoplasms pathology, Uterine Cervical Neoplasms surgery
- Abstract
Purpose: The purpose of this study was to assess the prognostic role and the perioperative outcomes of conization performed before radical hysterectomy in early-stage cervical carcinoma., Methods: This multicenter, retrospective observational cohort study included patients with FIGO 2009 stage IB1 cervical carcinoma treated with radical hysterectomy between June 2004 and June 2019. Patients were divided into two groups according to conization before radical surgery. One-to-one case-control matching was used to adjust the baseline characteristics., Results: A total of 332 patients were included after propensity matching (166, 50% in each group). Twenty-four of 166 (14.4%) and 142 of 166 (85.6%) conization patients had negative and positive surgical margins on the conization specimen, respectively. No difference in intra- and postoperative complications was noted between the two groups (p = 0.542 and p = 0.180, respectively). Patients undergoing conization before radical hysterectomy received less adjuvant treatment (p < 0.001) and had a better 5-year disease-free survival (DFS) than patients who did not receive conization (89.8% vs. 80.0%, respectively; p = 0.010). No difference in 5-year overall survival (OS) (97.1% vs. 91.4%, respectively; p = 0.114) or recurrence pattern (p = 0.115) was reported between the two groups. Factors independently related to higher risk of recurrence were pathologic tumor diameter >20 mm and no conization before radical hysterectomy (p = 0.011 and p = 0.018, respectively). The only independent variable influencing OS was pathologic tumor diameter >20 mm (p = 0.020)., Conclusions: Conization before radical hysterectomy was associated with improved DFS and lower probability of receiving adjuvant treatment. No difference in perioperative complications and OS was evident. Tumor diameter >20 mm was found to be the only independent risk factor affecting OS in both groups.
- Published
- 2021
- Full Text
- View/download PDF
239. HPV and Cytology Testing in Women Undergoing 9-Valent HPV Opportunistic Vaccination: A Single-Cohort Follow Up Study.
- Author
-
De Vincenzo R, Caporale N, Bertoldo V, Ricci C, Evangelista MT, Bizzarri N, Pedone Anchora L, Scambia G, and Capelli G
- Abstract
Background : This study evaluates the possible effect of 9-valent (9vHPV) vaccination on the results of HPV and cytological tests in a cohort of adult women. Methods : This study is a retrospective, single-cohort, monocentric study. Sexually active women aged 14-70 years, who underwent 9vHPV vaccination, were enrolled. Dose administration dates, side effects and data on Pap smears and HPV tests performed before and after the first vaccine dose were collected. Subjects were considered "unexposed" to the vaccine for all time intervals before the first dose administration, and "exposed" to the first, second and third vaccine doses in all time intervals following each specific dose. Results : A total of 512 women underwent the first 9vHPV dose administration and were enrolled in the study. Median age at vaccination was 30.5 (14-70). Log-rank tests and Cox regression analyses showed a highly statistically significant ( p < 0.0001) difference in the time to negativization after the exposure to the third vaccine dose in the 207 women starting with a Pap+ smear (HR (95% C.I.), 2.66 (1.83-3.86)) and in the 198 women starting with an HPV HR+ test (HR (95% C.I.), 7.80 (4.83-12.60)). Conclusions : 9vHPV vaccination may play a role in shortening the clearance time of HPV HR+ or Pap positivity in sexually active adult women.
- Published
- 2021
- Full Text
- View/download PDF
240. High-risk HPV-positive and -negative high-grade cervical dysplasia: Analysis of 5-year outcomes.
- Author
-
Bogani G, Sopracordevole F, Di Donato V, Ciavattini A, Ghelardi A, Lopez S, Simoncini T, Plotti F, Casarin J, Serati M, Pinelli C, Valenti G, Bergamini A, Gardella B, Dell'acqua A, Monti E, Vercellini P, Fischetti M, D'ippolito G, Aguzzoli L, Mandato VD, Carunchio P, Carlinfante G, Giannella L, Scaffa C, Falcone F, Borghi C, Ditto A, Malzoni M, Giannini A, Salerno MG, Liberale V, Contino B, Donfrancesco C, Desiato M, Perrone AM, Dondi G, De Iaco P, Chiappa V, Ferrero S, Sarpietro G, Matarazzo MG, Cianci A, Bosio S, Ruisi S, Guerrisi R, Brusadelli C, Mosca L, Lagana' AS, Tinelli R, Signorelli M, De Vincenzo R, Zannoni GF, Ferrandina G, Lovati S, Petrillo M, Dessole S, Carlea A, Zullo F, Angioli R, Greggi S, Spinillo A, Ghezzi F, Colacurci N, Muzii L, Benedetti Panici P, Scambia G, and Raspagliesi F
- Subjects
- Adult, Conization, Female, Humans, Middle Aged, Papillomavirus Infections virology, Prognosis, Propensity Score, Retrospective Studies, Risk Factors, Uterine Cervical Dysplasia pathology, Uterine Cervical Neoplasms pathology, Young Adult, Papillomavirus Infections pathology, Uterine Cervical Dysplasia virology, Uterine Cervical Neoplasms virology
- Abstract
Objective: To evaluate the outcomes of high-risk (HR) HPV-positive and -negative women affected by high-grade cervical dysplasia., Methods: This is a retrospective multi-institutional study. Medical records of consecutive patients with high-grade cervical dysplasia undergoing conization between 2010 and 2014 were retrieved. All patients included had at least 5 years of follow-up. A propensity-score matching was adopted in order to reduce the presence of confounding factors between groups. Kaplan-Meir and Cox hazard models were used to estimate 5-year outcomes., Results: Overall, data of 2966 women, affected by high-grade cervical dysplasia were reviewed. The study population included 1478 (85%) and 260 (15%) women affected by HR-HPV-positive and HR-HPV-negative high-grade cervical dysplasia. The prevalence of CIN2 and CIN3 among the HR-HPV-positive and -negative cohort was similar (p = 0.315). Patients with HR-HPV-positive high-grade cervical dysplasia were at higher risk of 5-year recurrence (after primary conization) that HR-HPV-negative patients (p < 0.001, log-rank test). Via multivariate analysis, HR-HPV-negative women were at low risk of recurrence (HR: 1.69 (95%CI: 1.05, 4.80); p = 0.018, Cox Hazard model). A propensity-score matched comparison was carried out in order to reduce biases that are related to the retrospective study design. In comparison to HR-HPV-negative patients, thosewith HR-HPV-positive CIN3 was associate with a 8-fold increase in the risk of recurrence (p < 0.001, log-rank test)., Conclusions: HR-HPV-negative high-grade cervical dysplasia is not uncommon, accounting for 15% of our study population. Those patients experience more favorable outcomes than patients with documented HR-HPV infection(s). Further prospective studies are needed to corroborate our data., (Copyright © 2021 Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
241. Beyond the Nucleosome: Nucleosome-Protein Interactions and Higher Order Chromatin Structure.
- Author
-
Lobbia VR, Trueba Sanchez MC, and van Ingen H
- Subjects
- Chromobox Protein Homolog 5, Chromosomal Proteins, Non-Histone genetics, Chromosomal Proteins, Non-Histone metabolism, DNA genetics, DNA metabolism, Histones genetics, Histones metabolism, Humans, Molecular Dynamics Simulation, Nucleic Acid Conformation, Nucleosomes chemistry, Nucleosomes metabolism, Polycomb Repressive Complex 2 genetics, Polycomb Repressive Complex 2 metabolism, Protein Binding, Protein Conformation, alpha-Helical, Protein Conformation, beta-Strand, Protein Interaction Domains and Motifs, Static Electricity, Chromatin Assembly and Disassembly, Chromosomal Proteins, Non-Histone chemistry, DNA chemistry, Histones chemistry, Nucleosomes ultrastructure, Polycomb Repressive Complex 2 chemistry
- Abstract
The regulation of chromatin biology ultimately depends on the manipulation of its smallest subunit, the nucleosome. The proteins that bind and operate on the nucleosome do so, while their substrate is part of a polymer embedded in the dense nuclear environment. Their molecular interactions must in some way be tuned to deal with this complexity. Due to the rapid increase in the number of high-resolution structures of nucleosome-protein complexes and the increasing understanding of the cellular chromatin structure, it is starting to become clearer how chromatin factors operate in this complex environment. In this review, we analyze the current literature on the interplay between nucleosome-protein interactions and higher-order chromatin structure. We examine in what way nucleosomes-protein interactions can affect and can be affected by chromatin organization at the oligonucleosomal level. In addition, we review the characteristics of nucleosome-protein interactions that can cause phase separation of chromatin. Throughout, we hope to illustrate the exciting challenges in characterizing nucleosome-protein interactions beyond the nucleosome., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
242. Neoadjuvant chemotherapy followed by conization in stage IB2-IIA1 cervical cancer larger than 2 cm: a pilot study.
- Author
-
de Vincenzo R, Ricci C, Fanfani F, Gui B, Gallotta V, Fagotti A, Ferrandina G, and Scambia G
- Subjects
- Adolescent, Adult, Cisplatin therapeutic use, Disease-Free Survival, Feasibility Studies, Female, Fertility Preservation methods, Humans, Neoadjuvant Therapy, Neoplasm Recurrence, Local epidemiology, Neoplasm Staging, Organ Sparing Treatments methods, Paclitaxel therapeutic use, Patient Acceptance of Health Care statistics & numerical data, Pilot Projects, Pregnancy, Pregnancy Rate, Tumor Burden, Young Adult, Adenocarcinoma drug therapy, Adenocarcinoma epidemiology, Adenocarcinoma pathology, Adenocarcinoma surgery, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carcinoma, Squamous Cell drug therapy, Carcinoma, Squamous Cell epidemiology, Carcinoma, Squamous Cell pathology, Carcinoma, Squamous Cell surgery, Conization, Uterine Cervical Neoplasms drug therapy, Uterine Cervical Neoplasms epidemiology, Uterine Cervical Neoplasms pathology, Uterine Cervical Neoplasms surgery
- Abstract
Objective: To evaluate feasibility of neoadjuvant chemotherapy (NACT) followed by cold-knife conization (CKC) in patients with 2018 FIGO stage IB2-IIA1 cervical cancer who desired to maintain fertility., Design: Pilot study of conization after chemotherapy in stage IB2-IIA1 >2 cm cervical cancer., Setting: University hospital., Patient(s): From 2014 to 2018, 25 patients, <40 years of age, were enrolled., Interventions(s): After laparoscopic pelvic lymph-node assessment, NACT with cisplatin/paclitaxel q21 was administered to eligible patients. Responsive patients were treated with CKC., Main Outcome Measure(s): Obstetrical outcome: pregnancy rate. Oncologic outcome., Result(s): Thirteen out of 25 patients were eligible for fertility-sparing treatment. Oncologic outcome: The clinical overall response rate was 84.5% (11 out of 13 patients). One patient achieved stable disease, was managed by radical surgery, and is still alive; another one experienced progression of disease and died after 15 months. The optimal pathologic response was 69.1%. In the setting of fertility preservation patients, the median follow-up was 37 months (range 18-76). In this group we registered one distant recurrence, 12 months after CKC, in the liver; the patient is still alive and without evidence of disease. Obstetrical outcome: Among the nine patients amenable, three tried to conceive, and two spontaneous pregnancy occurred a few months after the end of treatment, for a pregnancy rate of 66.7%., Conclusion(s): This pilot study supports the feasibility of CKC after NACT as conservative treatment in stage IB2-IIA1 cervical cancer, with oncologic outcomes similar to those reported for trachelectomy in the same stage and with potential benefits in terms of obstetrical outcomes., Clinical Trial Registration Number: NCT02323841., (Copyright © 2020 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
243. Recurrence rate after loop electrosurgical excision procedure (LEEP) and laser Conization: A 5-year follow-up study.
- Author
-
Bogani G, DI Donato V, Sopracordevole F, Ciavattini A, Ghelardi A, Lopez S, Simoncini T, Plotti F, Casarin J, Serati M, Pinelli C, Valenti G, Bergamini A, Gardella B, Dell'acqua A, Monti E, Vercellini P, Fischetti M, D'Ippolito G, Aguzzoli L, Mandato VD, Carunchio P, Carlinfante G, Giannella L, Scaffa C, Falcone F, Borghi C, Ditto A, Malzoni M, Giannini A, Salerno MG, Liberale V, Contino B, Donfrancesco C, Desiato M, Perrone AM, Dondi G, De Iaco P, Leone Roberti Maggiore U, Signorelli M, Chiappa V, Ferrero S, Sarpietro G, Matarazzo MG, Cianci A, Bosio S, Ruisi S, Guerrisi R, Brusadelli C, Mosca L, Tinelli R, DE Vincenzo R, Zannoni GF, Ferrandina G, Petrillo M, Dessole S, Angioli R, Greggi S, Spinillo A, Ghezzi F, Colacurci N, Muzii L, Benedetti Panici P, Scambia G, and Raspagliesi F
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Cervix Uteri pathology, Cervix Uteri surgery, Cervix Uteri virology, Conization instrumentation, Electrosurgery instrumentation, Female, Follow-Up Studies, Humans, Lasers, Margins of Excision, Middle Aged, Neoplasm Grading, Neoplasm Recurrence, Local prevention & control, Neoplasm Recurrence, Local virology, Neoplasm, Residual, Papillomavirus Infections pathology, Papillomavirus Infections surgery, Papillomavirus Infections virology, Retrospective Studies, Risk Factors, Uterine Cervical Neoplasms diagnosis, Uterine Cervical Neoplasms epidemiology, Uterine Cervical Neoplasms virology, Young Adult, Uterine Cervical Dysplasia diagnosis, Uterine Cervical Dysplasia epidemiology, Uterine Cervical Dysplasia virology, Conization methods, Electrosurgery methods, Neoplasm Recurrence, Local epidemiology, Papillomavirus Infections epidemiology, Uterine Cervical Neoplasms surgery, Uterine Cervical Dysplasia surgery
- Abstract
Objective: Conization aims to remove pre-neoplastic lesions of the uterine cervix. Several techniques for conization have been compared, but evidence regarding the most effective therapeutic option is scant. Here, we aimed to compare the recurrence rate following laser conization and loop electrosurgical excision procedure (LEEP) in patients with high-grade cervical dysplasia (HSIL/CIN2+)., Methods: This is a retrospective multi-institutional study. Medical records of consecutive patients with HSIL/CIN2+ undergoing conization between 2010 and 2014 were retrieved. A propensity-score matching (PSM) was applied in order to reduce allocation bias. The risk of developing recurrence was estimated using Kaplan-Meir and Cox hazard models., Results: Overall, 2966 patients had conization over the study period, including 567 (20%) and 2399 (80%) patients having laser conization and LEEP, respectively. Looking at predictors of recurrence, diagnosis of CIN3 (HR:3.80 (95%CI:2.01,7.21); p < 0.001) and HPV persistence (HR:1.81 (95%CI:1.11,2.96); p < 0.001) correlated with an increased risk of recurrence. After applying a PSM we selected 500 patients undergoing laser conization and 1000 undergoing LEEP. Patients undergoing LEEP were at higher risk of having positive surgical margins in comparison to patients undergoing laser conization (11.2% vs. 4.2%). The risk of having persistence of HPV was similar between the two groups (15.0% vs. 11.6%;p = 0.256). Five-year recurrence rate was 8.1% and 4% after LEEP and laser conization, respectively (p = 0.023). HPV persistence was the only factor associated with [5-]year recurrence after both laser conization (p = 0.003) and LEEP (p = 0.001)., Conclusions: HPV persistence is the only factor associated with an increased risk of recurrence after either laser conization or LEEP. Owing to the lack of data regarding obstetrical outcomes, we are not able to assess the best therapeutic option for women with cervical dysplasia., (Copyright © 2020. Published by Elsevier Inc.)
- Published
- 2020
- Full Text
- View/download PDF
244. Endocuff-assisted versus Cap-assisted Colonoscopy in Increasing Adenoma Detection Rate. A Meta-analysis.
- Author
-
Facciorusso A, Buccino VR, and Sacco R
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Equipment Design, Female, Humans, Male, Middle Aged, Predictive Value of Tests, Randomized Controlled Trials as Topic, Reproducibility of Results, Tumor Burden, Young Adult, Adenomatous Polyps pathology, Colonic Neoplasms pathology, Colonic Polyps pathology, Colonoscopes, Colonoscopy instrumentation
- Abstract
Background and Aims: Several add-on devices have been developed to increase rates of colon adenoma detection. We aimed to compare the endocuff-assisted colonoscopy with cap-assisted colonoscopy through a pairwise meta-analysis of randomized trials., Methods: We searched the PubMed/Medline and Embase database through March 2020 and identified 6 randomized controlled trials (comprising 2,027 patients). The primary outcome was adenoma detection rate; secondary outcomes included sessile serrated adenoma detection rate, mean adenoma per colonoscopy, cecal intubation rate and time to reach cecum. Safety data were also analyzed. We performed pairwise meta-analysis through a random effects model and expressed data as risk ratio and 95% confidence interval., Results: Overall, pooled adenoma detection rate was 48.1% (39.3-56.8%) with endocuff and 40.5% (30.4- 50.6%; risk ratio 1.14, 0.96-1.35) with cap. Proximal adenoma detection rate was 45.7% (36.8-54.7%) and 24% (17-45.1%) with endocuff and cap, respectively (risk ratio 2.04, 0.93-4.49), whereas endocuff outperformed cap-assisted colonoscopy in detecting diminutive (≤ 5 mm) adenomas (risk ratio 2.74, 1.53-4.90) and in terms of mean adenoma per colonoscopy (mean difference 0.31, 0.05 -0.57; p=0.02). Sessile serrated adenoma detection rate (risk ratio 1.36, 0.72-2.59), cecal intubation rate (risk ratio 0.99, 0.98-1.00), and time to reach cecum (6.87 min versus 6.87 min) were similar between the two groups. No serious adverse event was observed., Conclusion: Endocuff-assisted colonoscopy seems to provide a higher adenoma detection rate as compared to cap-assisted colonoscopy, in particular concerning smaller diminutive polyps.
- Published
- 2020
- Full Text
- View/download PDF
245. HPV Vaccination: The Position Paper of the Italian Society of Colposcopy and Cervico-Vaginal Pathology (SICPCV).
- Author
-
Ciavattini A, Giannella L, De Vincenzo R, Di Giuseppe J, Papiccio M, Lukic A, Delli Carpini G, Perino A, Frega A, Sopracordevole F, Barbero M, and Gultekin M
- Abstract
Human papillomavirus (HPV) related cervical cancer represents an issue of public health priority. The World Health Organization recommended the introduction of HPV vaccination in all national public programs. In Europe, vaccines against HPV have been available since 2006. In Italy, vaccination is recommended and has been freely offered to all young girls aged 11 years since 2008. Three prophylactic HPV vaccines are available against high- and low-risk genotypes. The quadrivalent vaccine contains protein antigens for HPV 6, 11, 16, and 18. The bivalent vaccine includes antigens for HPV 16 and 18. The nonavalent vaccine was introduced in 2014, and it targets HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58. Clinical trials demonstrated the effectiveness of the three vaccines in healthy young women. Likewise, all vaccines showed an excellent safety profile. The bivalent vaccine provides two doses in subjects aged between 9 and 14 years and three doses in subjects over 14 years of age. The quadrivalent vaccine provides two doses in individuals from 9 to 13 years and three doses in individuals aged 14 years and over. The nonavalent vaccine schedule provides two doses in individuals from 9 to 14 years of age and three doses in individuals aged 15 years and over at the time of the first administration. Preliminary results suggest that the HPV vaccine is effective in the prevention of cervical squamous intraepithelial lesions even after local treatment. Given these outcomes, in general, it is imperative to expand the vaccinated target population. Some interventions to improve the HPV vaccine's uptake include patient reminders, physicians-focused interventions, school-based vaccinations programs, and social marketing strategies. The Italian Society of Colposcopy and Cervico-Vaginal Pathology (SICPCV) is committed to supporting vaccination programs for children and adolescents with a catch-up program for young adults. The SICPCV also helps clinical and information initiatives in developing countries to decrease the incidence of cervico-vaginal and vulvar pathology.
- Published
- 2020
- Full Text
- View/download PDF
246. Dynamic ultrasound imaging of the posterior capsule in the shoulder: Tips and tricks.
- Author
-
Vincenzo R and Levent Ö
- Subjects
- Adult, Arthrography methods, Humans, Humeral Head anatomy & histology, Joint Capsule anatomy & histology, Male, Range of Motion, Articular physiology, Rotator Cuff anatomy & histology, Shoulder anatomy & histology, Shoulder Joint anatomy & histology, Ultrasonography methods, Humeral Head diagnostic imaging, Joint Capsule diagnostic imaging, Rotator Cuff diagnostic imaging, Shoulder diagnostic imaging, Shoulder Joint diagnostic imaging
- Published
- 2020
- Full Text
- View/download PDF
247. Expert consensus from the Italian Society for Colposcopy and Cervico-Vaginal Pathology (SICPCV) for colposcopy and outpatient surgery of the lower genital tract during the COVID-19 pandemic.
- Author
-
Ciavattini A, Delli Carpini G, Giannella L, De Vincenzo R, Frega A, Cattani P, Boselli F, Sopracordevole F, and Barbero M
- Subjects
- Adult, Biopsy, COVID-19, Consensus, Female, Genital Diseases, Female diagnosis, Genital Diseases, Female pathology, Humans, Italy, Mass Screening, Practice Guidelines as Topic, Pregnancy, Time Factors, Ambulatory Surgical Procedures standards, Colposcopy standards, Coronavirus Infections prevention & control, Coronavirus Infections transmission, Disease Transmission, Infectious prevention & control, Genital Diseases, Female surgery, Infection Control standards, Pandemics prevention & control, Pneumonia, Viral prevention & control, Pneumonia, Viral transmission
- Abstract
In the context of the COVID-19 pandemic, patients need to be evaluated within 2-4 weeks in the following cases: cytology result of "squamous cell carcinoma," "atypical glandular cells, favor neoplastic," "endocervical adenocarcinoma in situ," or "adenocarcinoma"; histopathological diagnosis of suspected invasion from cervical/vaginal biopsy, or invasive disease after a cervical excision procedure, vaginal excision, or vulvar biopsy/excision; sudden onset of strongly suggestive symptoms for malignancy. Digital imaging technologies represent an important opportunity during the COVID-19 pandemic to share colposcopic images with reference centers, with the aim of avoiding any concentration of patients. All patients must undergo screening for COVID-19 exposure and should wear a surgical mask. A high-efficiency filter smoke evacuation system is mandatory to remove surgical smoke. Electrosurgical instruments should be set at the lowest possible power and not be used for long continuous periods to reduce the amount of surgical smoke. The following personal protective equipment should be used: sterile fluid-repellant surgical gloves, an underlying pair of gloves, eye protection, FFP3 mask, surgical cap, and gown. The colposcope should be protected by a disposable transparent cover. A protective lens that must be disinfected after each use should be applied. The use of a video colposcope should be preferred., (© 2020 International Federation of Gynecology and Obstetrics.)
- Published
- 2020
- Full Text
- View/download PDF
248. MRI in pregnant patients with suspected abdominal and pelvic cancer: a practical guide for radiologists.
- Author
-
Gui B, Cambi F, Micco M, Sbarra M, Petta F, Autorino R, De Vincenzo R, Valentini V, Scambia G, and Manfredi R
- Subjects
- Abdominal Neoplasms epidemiology, Abdominal Neoplasms pathology, Adult, Contrast Media, Female, Gestational Age, Humans, Incidence, Magnetic Resonance Imaging statistics & numerical data, Neoplasm Staging methods, Patient Positioning methods, Patient Preference psychology, Pelvic Neoplasms epidemiology, Pelvic Neoplasms pathology, Precision Medicine methods, Pregnancy, Radiologists statistics & numerical data, Safety, Watchful Waiting standards, Abdomen pathology, Abdominal Neoplasms diagnostic imaging, Magnetic Resonance Imaging methods, Pelvic Neoplasms diagnostic imaging, Pelvis pathology, Radiologists education
- Abstract
The incidence of abdominal and pelvic cancer in pregnancy is low, but it is rising as the population of pregnant women gets older. Depending on disease stage, gestational age and patient's preference, active surveillance as well as surgery and chemotherapy are feasible options during pregnancy. Correct diagnosis and staging of the tumor is crucial for choosing the best therapeutic approach. Moreover, a reproducible modality to assess the treatment response is requested. Magnetic resonance imaging (MRI) is commonly used with good results for the local staging and treatment response evaluation of most abdominal and pelvic cancers in nonpregnant patients, and it is considered relatively safe during pregnancy. The purpose of this article is to analyze the most relevant topics regarding the use of MRI in pregnant women with abdominal and pelvic cancer. We discuss MRI safety during pregnancy, including the use of gadolinium-based contrast agents (GBCAs), how to prepare the patient for the exam and MRI technique. This will be followed by a brief review on the most common malignancies diagnosed during pregnancy and their MRI appearance.
- Published
- 2020
- Full Text
- View/download PDF
249. Ramified rolling circle amplification for synthesis of nucleosomal DNA sequences.
- Author
-
van Emmerik CL, Gachulincova I, Lobbia VR, Daniëls MA, Heus HA, Soufi A, Nelissen FHT, and van Ingen H
- Subjects
- Histones genetics, Humans, Nucleosomes genetics, Octamer Transcription Factor-3 genetics, RNA-Binding Proteins genetics, DNA, Recombinant chemical synthesis, Nucleic Acid Amplification Techniques methods
- Abstract
Nucleosomes are a crucial platform for the recruitment and assembly of protein complexes that process the DNA. Mechanistic and structural in vitro studies typically rely on recombinant nucleosomes that are reconstituted using artificial, strong-positioning DNA sequences. To facilitate such studies on native, genomic nucleosomes, there is a need for methods to produce any desired DNA sequence in an efficient manner. The current methods either do not offer much flexibility in choice of sequence or are less efficient in yield and labor. Here, we show that ramified rolling circle amplification (RCA) can be used to produce milligram amounts of a genomic nucleosomal DNA fragment in a scalable, one-pot reaction overnight. The protocol is efficient and flexible in choice of DNA sequence. It yields 10-fold more product than PCR, and rivals production using plasmids. We demonstrate the approach by producing the genomic DNA from the human LIN28B locus and show that it forms functional nucleosomes capable of binding pioneer transcription factor Oct4., (Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
250. Prevalence of cervical HPV and attitude towards cervical screening in IBD patients under immunomodulatory treatment: a multidisciplinary management experience.
- Author
-
Ricci C, Scaldaferri F, Colombo F, Armuzzi A, Lopetuso LR, Leone S, Gasbarrini A, Scambia G, and De Vincenzo RP
- Subjects
- Adolescent, Adult, Alphapapillomavirus, Cross-Sectional Studies, Disease Management, Early Detection of Cancer methods, Female, Humans, Immunologic Factors adverse effects, Inflammatory Bowel Diseases drug therapy, Papillomavirus Infections diagnosis, Prevalence, Prospective Studies, Treatment Outcome, Uterine Cervical Neoplasms diagnosis, Uterine Cervical Neoplasms epidemiology, Young Adult, Attitude of Health Personnel, Early Detection of Cancer trends, Immunologic Factors administration & dosage, Inflammatory Bowel Diseases epidemiology, Papillomavirus Infections epidemiology, Patient Care Team trends
- Abstract
Objective: Therapeutic strategies for Inflammatory Bowel Diseases (IBD: Crohn's disease and Ulcerative Colitis) have improved but the risk for HPV infection in patients under immunomodulatory/biologic treatment is unclear. Objective of the study is to identify the attitude of patients and caregivers to cervical screening. To determine the prevalence of HPV and cervical lesions in IBD patients receiving immunomodulatory/biological treatment., Patients and Methods: IBD patients treated with immunomodulators were enrolled from November 2016 to September 2017, thanks to a multidisciplinary cooperation. A survey was administered to enrolled patients as well as to a selected network of IBD expert physicians. Patients who consented underwent gynecological examination, smear, HPV DNA test, colposcopy, vaginal and cervical microbiological swabs., Results: 294 patients from AMICI Onlus Association, 119 patients from the hospital clinic, 30 doctors from national IBD centers participated to the survey. 19 patients from the IBD clinic underwent cervical screening. More than 90% of doctors consider their patients at risk of cervical cancer. A low prevalence of high-risk genotypes and related HPV lesions and an increased prevalence of bacterial vaginosis emerged in the studied population., Conclusions: Biological drugs could lead to a positive immunomodulation towards HPV infection. In IBD patients an alteration of the vaginal and intestinal microbiota seems to be coexisting.
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.